Citrate-based ocular implants and polymers

Abstract

The present disclosure provides ocular implants, polymers or oligomers which may be used in said implants, and methods of treating ophthalmic disorders with the same.

Description

[0001]Attorney Docket No.11196-112WO1 CITRATE-BASED OCULAR IMPLANTS AND POLYMERS CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to United States Provisional Patent Application No. 63 / 590,045, filed October 13, 2023, the disclosure of which is incorporated herein by reference in its entirety. BACKGROUND There are 3.7M cataract surgeries per year in the U.S. However, postoperative complications do occur and include inflammation (> 95% of patients), cystoid macular edema (2%), and infection (endophthalmitis, 0.2%). To mitigate these complications, patients are prescribed eye drops that need to be applied multiple times a day for at least 30 days. Many patients struggle to effectively administer these eye drops with misapplication resulting in 93% of patients, while more than 50% of patients are non-compliant, often due to comorbidities of advanced age. This is not only a problem for the patient - clinical staff spends over 3,000 hours fielding calls regarding eye drops, and surgeons manage complications ranging from delayed healing to compromised vision. Globally, cataracts (defined by opacification of the natural transparent ocular lens) rank as the most significant cause of visual impairment and blindness. As a result, cataract surgery is the most commonly performed invasive ambulatory surgery in the USA, addressing more than 24.4 million occurrences in the ≥40 age group (>94 million worldwide). By age 75, approximately half of all Americans will have developed visually significant cataracts. Small-incision cataract surgery using phacoemulsification (breakup and removal of the opacified lens followed by replacement with an artificial intraocular implant) has become the standard of care, with new developments in surgical techniques and instrumentation contributing to excellent clinical outcomes and rendering cataract surgery one of the most cost-effective procedures in healthcare; however, significant postoperative complications occur, including inflammation (>95%), elevated intraocular pressure (2.3%), cystoid macular edema (1.95%), and infection-mediated inflammation (endophthalmitis, 0.2%). Within the span of surgery and continuing in the post-surgical phase, damaged cells release factors triggering the inflammatory cascade along with chemokines and growth factors, attracting inflammatory cells including monocytes, which further differentiate into macrophages, assuming the key role in subsequent inflammation. While a normal response to tissue damage, such inflammation in the acute stage leads to Attorney Docket No.11196-112WO1 significant patient discomfort (reported in >50% of patients) while, if left unchecked and / or complicated by other risk factors (such as infection), the desired acute response may readily transition to a chronic reaction, leading to serious additional consequences, including vision loss in extreme cases. Canonically, administration of steroids, such as dexamethasone, served to reduce post-surgical inflammation; however, steroid usage is associated with significant side effects, including depressed host response leading to risk of bacterial and fungal infections, exacerbation of viral infections (i.e. herpes simplex) and, ironically, increased IOP and delayed healing. As an alternative, non-steroidal anti-inflammatory drugs (NSAIDs), such as bromfenac, have been widely adopted. Inhibiting the cyclo-oxygenase-2 (COX-2) mediated breakdown of arachidonic acid (a product of inflammatory mediated cell membrane phospholipid breakdown) to prostaglandin (PGE), responsible for miosis (excessive pupil narrowing), increased vascular permeability, IOP modulation, and promotion of inflammatory macrophage activation, NSAIDs have been effective mediators of post-surgical inflammation. Despite their demonstrated capabilities, effective delivery of NSAIDs is critically limited, systemic delivery being hampered by ineffective targeting, minimal ability to cross the blood-ocular tissue barrier, and off target effects on global COX pathways (necessary in non-inflamed tissue for homeostasis) within the kidney, gastrointestinal tract, liver, and other organs. As a result, local delivery is the preferred treatment method, however, development of an effective delivery system remains a critical challenge. Topical eye drops, currently accounting for ~90% of ophthalmic medications, display limited bioavailability (<5%) due to rapid clearance (1-2 minutes) via continuous removal by tears, significantly reducing effectiveness. More critically, the self- administration of such treatments contributes to variable and misapplication in up to 92.6% of patients (due to variable drop volume, bottle angle, and squeeze pressure) as well as non- compliance (>50% of patients), negatively impacting treatment and consuming 3000 staff hours per year responding to calls regarding post cataract surgery eye drops. Techniques focusing on increasing bioavailability and residence time, such as increased drug concentration and administration frequency, use of lipophilic drugs or nanoparticle delivery systems, and increased drug absorption, largely fail due to decreased compliance, improper shaking of lipophilic suspensions (and thus dose variability), and increased off-target effects on sensitive eye structures, respectively. In contrast, continuous delivery of anti- inflammatory drugs via implants offers a consistent, passive compliance alternative to Attorney Docket No.11196-112WO1 current treatments. Previous attempts to develop such implants have been limited, such as non-degradable contact lens impregnated with bromfenac. While such implants proved capable of replacing currently utilized drops via weekly administration (2-6 lenses versus 14-42 and 28-84 drops for once daily and twice daily formulations over a typical 2–6-week treatment), they are still incapable of removing the necessity for patient compliance and proper self- administration. Biodegradable injectable hydrogels and biodegradable subconjunctival solid implants offer a fully resorbable alternative, however, the former have difficulty sustaining drug release past 1 – 2 weeks, again necessitating replacement, while both are invasive (requiring injection by a healthcare professional). Additionally, removal of such implants is nearly impossible without causing additional trauma. Most recently, intracanalicular implants have gained increasing attention. Easily inserted within the canaliculus duct (responsible for drainage of tears from the eye), such implants swell in response to uptake of tear fluid, lodging them safely within the duct, where constant exposure to said fluid mediates continuous release of incorporated drugs into the eye until the remnants of the degraded implant are washed into the nasolacrimal duct (such devices are also easily removed using tweezers if necessary). One such device recently approved by the FDA composed of a poly(ethylene glycol) network incorporating dexamethasone, has been shown to deliver therapeutically relevant doses in vitro and in vivo over a period of one month followed by complete degradation, reducing inflammation as effectively as topical drop controls; however, this system: (1) utilizes steroids, associated with significant side effects, (2) as a solid implant blocks the intracanalicular duct, leading to possible eye watering, swelling, and infection, (3) is a weak hydrogel, and (4) is composed of a passive material lending no benefit to inflammatory or infection control. Such limitations necessitate development of a material / delivery system tailored for the post-surgery ocular environment. SUMMARY This disclosure provides implants, polymers or oligomers, and their use in treating medical disoders. In particular, the present disclosure provides ocular implants, polymers or oligomers which may be used in preparing said implants, and their use in treating ophthalmic disorders. In one aspect, an ocular implant is provided. In some aspects, the ocular implant comprises a polymer or oligomer. In some aspects, the polymer or oligomer is formed from Attorney Docket No.11196-112WO1 citric acid, or a salt or derivative thereof. In some aspects, the polymer or oligomer is further formed from 1,8-octanediol. In some aspects, the polymer or oligomer is further formed from xylitol. In some aspects, the polymer or oligomer is further formed from optionally one or more additional monomers. In another aspect, a polymer or oligomer is provided formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; ascorbic acid, or a salt or derivative thereof; and optionally one or more additional monomers. In a further aspect, a polymer or oligomer is provided formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; one or more therapeutic agents; and optionally one or more additional monomers. In another aspect, a method is provided of treating an ophthalmic disorder in a subject in need thereof. In some aspects, the method comprises administering to the subject an ocular implant or polymer / oligomer described herein. The details of one or more aspect of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the disclosure will be apparent from the description, the drawings, and the claims. DESCRIPTION OF DRAWINGS FIGs. 1A and 1B depict an exemplary ocular implant of the disclosure and its placement the intracanalicular duct of a human eye. FIG. 2 depicts an exemplary structure of POC-Xylitol (POC-X) and the constituent monomers used in the preparation of the same. POC-X is synthesized from the monomers citric acid, xylitol, and octanediol, each of which has demonstrated biocompatibility as well as anti-oxidant and anti-microbial potentials in the case of citric acid and anti-oxidant properties in the case of xylitol. FIG.3 depicts an exemplary synthetic scheme for the preparation of POC-X. POC-X is synthesized via a one step, catalyst free polycondensation reaction of the combined monomers in the desired ratio via melting at 160°C for 10 minutes followed by polymerization at 140°C until reaction termination. The resulting prepolymer is then dissolved in an organic solvent followed by either lyophilization or purification via precipitation in deionized (DI) water and subsequent lyophilization. Dried prepolymer is then dissolved in an appropriate organic solvent for further use. Attorney Docket No.11196-112WO1 FIG. 4 depicts the POX-C branched prepolymer network. The resulting prepolymer network comprises linear repeat units, branched crosslinking points (ester bonds) and pendent functional groups (hydroxyl and carboxyl groups) allowing further network functionalization or thermal crosslinking to form solid polymers. FIG. 5 is a table providing the ratio of monomers for the preparation of POC and POC-X compositions X1, X3, X5, and X6 as described in the examples. FIGs.6A, 6B, and 6C depict how xylitol content increases polymer network density. POC-X provides a high strength, rapidly degradable polymer by simultaneously increasing crosslinking density and hydrophilicity via xylitol incorporation. FIG. 7 depicts how xylitol incorporation results in an increasingly branched and dense prepolymer and polymer network. FIGs. 8A and 8B depict how tuning the xylitol feeding ratio and thermal crosslinking time modulates mechanics and swelling ratios. FIG. 9 depicts how increasing crosslinking density can counteract hydrophilicity even at high xylitol contents and results in minimal or maximal volume increase as desired. FIGs. 10A, 10B, and 10C depict how xylitol containing polymers display biphasic mechanics. The polymers have high mechanical strength and rigidity in the dry state followed by softening into a compliant elastomer in the hydrated state. Such polymers ensure damage free implantation while minimizing irritation and soft tissue damage during treatment. Xylitol containing polymers also maintain higher strengths than POC at all time points. FIGs. 11A, 11B, and 11C depict how increasing xylitol feeding ratio increases hydrophilicity and thus degradation rate while simultaneously increasing inter / intramolecular interactions and fluorescence. FIGs. 12A and 12B depict how toxicity of the leachable fraction of Xylitol containing polymers (small molecules released into cell culture media from polymer disks over 24 hours) was significantly decreased against both L929 and RAW 264.7 cells compared to POC. FIG. 13 depicts how the proliferation of L9292 cells on xylitol was significantly increased compared to POC. Attorney Docket No.11196-112WO1 FIG. 14 depicts how xylitol containing polymer films display complete inhibition of both gram positive and gram negative bacteria, indicating significant intrinsic antimicrobial properties. FIG. 15 depicts non-polarized macrophage cells growing on polymer films following 24 hr LPS stimulation. Compared to POC, xylitol containing films didn’t induce morphology change for non-polarized macrophages. Scale bar = 30 um and 10 um for top and bottom rows, respectively. FIG. 16 depicts how high strength and high strength to weight ratios are further demonstrated. A single X3 polymer strip weighing approximately 150mg is capable of holding 10lbs of weight. Additionally, the rigid to elastic material transition is further demonstrated following incubation in simulated tear fluid for 24 hours. FIG. 17 is a table providing the composition of simulated tear fluid as used in the examples. FIGs. 18A, 18B, and 18C depict that xylitol containing polymers (X3) have significant fluorescence and that polymer films display significant blue, red, and green fluorescence. Additionally, the ability to utilize laser cutting to create complex geometries from xylitol films indicates significant fabrication potential FIGs.19A and 19B provide the structure of the monomer ascorbic acid (AA) and the resulting dark black film capable of laser cutting into complex shapes for AA-incorporating xylitol polymers. FIG. 20 provides an exemplary chemical structure for an AA-incorporating polymer (X3AA). FIGs. 21A and 21B depict how POC-X-AA prepolymer and polymer maintains fluorescence properties while displaying significantly enhanced absorbance. FIGs. 22A and 22B depict how POC-X-AA has significant NIR absorbance compared to POC and X3 with a concentration dependent increase in absorbance. FIGs. 23A and 23B depict how strong NIR absorbance of POC-X-AA led to exploration of its photoacoustic imaging properties in agar tissue phantoms at ~2.5 cm depth using a photoacoustic / ultrasound imaging system. Attorney Docket No.11196-112WO1 FIGs. 24A, 24B, and 24C depict how both X3-AA prepolymer and films display significant photoacoustic signal from 700nm to 950nm, indicating photoacoustic and photothermal applications for imaging and therapy, respectively FIGs. 25A and 25B depict how X3-AA films display significant absorbance from 250nm to 1100nm. X3 films display significant absorbance in the UV region from 250nm to 400nm as well. Thus, films could also be used to block harmful UV light while in the case of X3 allowing transparency in the visible region. FIG. 26A and 26B depict how X3 blocks UV light while allowing transmission of visible light (450nm-660nm). X3-AA has significant absorbance from 700nm to 1000nm (NIR region). These results further display the ability to block UV light as described above while also allowing visible light transmission or strong absorbance in the visible to NIR regions depending on requirement. FIG. 27A, 27B, 27C, and 27D depict incorporation of cysteine, forming the fluorophore CA-Cys can further increase fluorescence of prepolymers and films for more effective imaging (X3-Cys). FIG. 28 provides an exemplary structure of polymer incorporating cysteine (X3- Cys). FIG. 29 depicts the incorporation of bromfenac into POC-Xylitol. Na-Bromfenac is either incorporated into initial prepolymer synthesis or mixed as a powder into pre-reacted prepolymer at 10wt% (X3B10). FIG. 30 depicts how homogeneous films of POC-X3-B10 and POC-X3-AA-B10 mixed and POC-X3-B10 reacted were obtained following thermal crosslinking. In order to homogenize films, the majority of solvent was evaporated then 5 mL of ethanol was added to the prepolymer. The prepolymer was then physically mixed and flattened into a film in Teflon dishes. Ethanol was evaporated and the films were then crosslinked. Resulting films were mostly homogenous. FIG. 31A and 31B depict how FTIR analysis revealed Bromfenac incorporation in both prepolymers and films of POC-X3-B10. FIG. 32 depicts how UV-VIS revealed Bromfenac incorporation in POC-X3-B10 rxn prepolymer while Bromfenac release was detected from POC-X3-B10 rxn films following incubation in simulated tear fluid for up to 7 days. Attorney Docket No.11196-112WO1 FIG.33 depicts the degradation and bromfenac release in simulated tear fluid. Rapid degradation of polymer at low crosslinking conditions (4 weeks) resulted in precipitation of free drug or drug containing oligomers. The calcium salt of bromfenac possibly formed, resulting in lower solubility. FIG. 34 depicts how prepolymers can be combined with NaCl salt followed by thermal crosslinking and salt leaching to form porous implants of sizes similar to commercial intracanalicular implants, displaying significant fluorescence. FIG. 35 depicts how highly reactive hexamethylene diisocyanate (HDI) can be used to create self-setting urethane doped polyester (sCUPEs) where the primary citrate polyester is crosslinked by a secondary urethane network at room temperature without catalyst. FIG. 36 depicts how liquid prepolymer solutions and HDI can be injection molded as pure polymers or composites containing salt or hydroxyapatite particles to create controlled implant morphologies. FIGs. 37A and 37B depict how microfluidic mixers can be used to create gelatin methacrylate microparticles loaded with drugs (Rhodamine B in the example) for incorporation within polymer implants to further modulate drug release. FIG. 38A and 38B depict how the microparticles can be injected through a 23G surgical needle, indicating capability as injectable intravitreal or transscleral implants. FIG. 39 is an exemplary synthetic scheme depicting the preparation of POC-xylitol- itaconate (POC-X-I). FIG. 40 is an exemplary synthetic scheme depicting the preparation of poly(octamethylene itaconate-xylitol) (POI-X). FIG. 41 is an exemplary presentation of a drug eluting citrate-based intracanalicular implant which releases bromfenac. FIG. 42 is an exemplary presentation of a drug eluting citrate-based intracanalicular implant which releases bromfenac-containing microspheres. FIG.43 is an exemplary presentation of a multifunctional intracanalicular implant. FIG. 44 is an exemplary chemical structure of a POC polymer capable of multiple drug release, exemplified with prednisolone and bromfenac. Attorney Docket No.11196-112WO1 FIG. 45 provides exemplary structures of an intracanalicular implant as described herein having a tapered design. FIGs. 46A, 46B, and 46C provide bromfenac release data from citrate-based polymers (concentration, ug / mg sample, and % release in FIGs. 46A, 46B, and 46C, respectively). This data demonstrates bromfenac release occurs over a period of at least 4 weeks (within desired treatment window for post-surgical inflammation) and occurs in a nearly linear fashion. FIG. 47 depicts both that bromfenac containing citrate-based polymers swell significantly upon incubation in simulated tear fluid but that they remain stable for up to 7 weeks (greater than the desired treatment time of 4 weeks). Additionally, the stability of X2AAB10 mix for 7 weeks combined with its greater swelling and rapid dissolution from 7 to 9 weeks suggests advantageous material properties for the given application in that the implant is expected to remain stable and lodged within the desired location for the entire treatment time (4 weeks) while rapidly being eliminated following treatment time (within 8 – 9 weeks). This could be considered favorable compared to current commercial implants, which take 3 months to degrade (increasing residence time and possible irritation past the necessary treatment window). It should be noted that this combined with the drug release data implies that citrate-based implants are capable of releasing therapeutic levels of bromfenac for a period greater than 4 weeks (compared to 100% dexamethasone release within four weeks for the current commercial implants), which when combined with the readily tunable degradation rates of citrate-xylitol based polymers should enable longer treatment times to combat other disease states (for instance, X3B10 mix has a preliminary degradation rate of 13-14 weeks while still releasing similar amounts of bromfenac compared to X3AAB10 mix for the first four weeks, suggesting functional drug release for up to 3 months). FIGs.48A, 48B, 48C, and 48D provide an extension of the photoacoustic / ultrasound results. In addition to a high PAUS signal arising from the incorporation of ascorbic acid (AA), incorporation of bromfenac itself results in significant absorbance in the NIR I window (FIGs. 48A and 48B) with addition of both AA and bromfenac in particular achieve high absorbance from 700-900 nm (FIG. 48C) as a result of its dark brown / black color (FIG.48D). Attorney Docket No.11196-112WO1 FIG. 49 provides a proposed mechanism of the reaction of citric acid with the primary amine of bromfenac, resulting in a molecule with a significant conjugation system resulting in broad absorbance as indicated by the dark brown / black color of the material. FIG. 50 depicts an improved molding technique achieving an implant of desired shape and size. FIG. 51 depicts the capability to mold citrate-xylitol based implants with results similar to a commercially available implant. FIG. 52 depicts the fabrication of tapers implants utilizing the molding methods described herein. FIGs. 53A, 53B, 53C, and 53D provide the final base material formulation for ascorbic acid conjugated elastomer X3AA and the associated degradation and swelling properties. Conjugation was via a one step reaction. Improved color contrast and antioxidant effects were observed. FIG.54 provides the compositions tested as described in FIGs.55A to 57B. * means that the composition was crosslinked with hexyl diisocyanate (HDI) and is a self-setting polyurethane. FIGs. 55A and 55B depict: (FIG. 55A) L929 cells were incubated for 24 hours with various dilutions of degradation products from POC, POCX3, POCX3AA, Bromfenac 10 (POCX3AA Bromfenac 10), and Bromfenac 20 (POCX3AA Bromfenac 20). The Y-axis represents the relative cell viability compared to cells cultured in medium without the addition of degradation solution or products. (FIG. 55B) B-3 cells were incubated for 24 hours with various dilutions of degradation products from POC, POCX3, POCX3AA, Bromfenac 10 (POCX3AA Bromfenac 10), and Bromfenac 20 (POCX3AA Bromfenac 20). The Y-axis represents the relative cell viability compared to cells cultured in medium without the addition of degradation solution or products. Degradation solution (2M NaOH ph7.4) at 1x dilution was added as a control. FIGs. 56A and 56B depict: (FIG. 56A) L929 cells were incubated for 24 hours with various dilutions of leachable products from POC, POCX3, POCX3AA, Bromfenac 10 (POCX3AA Bromfenac 10), and Bromfenac 20 (POCX3AA Bromfenac 20). The Y-axis represents the relative cell viability compared to cells cultured in medium without leachable products. (FIG. 56B) B-3 cells were incubated for 24 hours with various dilutions of degradation products from POC, POCX3, POCX3AA, Bromfenac 10 (POCX3AA Attorney Docket No.11196-112WO1 Bromfenac 10), and Bromfenac 20 (POCX3AA Bromfenac 20). The Y-axis represents the relative cell viability compared to cells cultured in medium without leachable products. FIGs.57A and 57B depict: (FIG.57A) L929 cells were incubated for 1, 2 and 3 days with various dilutions of leachable products from POC, POCX3, POCX3AA, Bromfenac 10 (POCX3AA Bromfenac 10), and Bromfenac 20 (POCX3AA Bromfenac 20). The Y-axis represents the OD450 reading of CCK8 assay of each day. NC stands for negative control, cells cultured in culture medium without leachable products. (FIG. 57B) B-3 cells were incubated for 24 hours with various dilutions of degradation products from POC, POCX3, POCX3AA, Bromfenac 10 (POCX3AA Bromfenac 10), and Bromfenac 20 (POCX3AA Bromfenac 20). The Y-axis represents the OD450 reading of CCK8 assay of each day. NC stands for negative control, cells cultured in culture medium without leachable products. FIGs. 58A, 58B, and 58C show that incorporation of antioxidant ascorbic acid to CXBEs (X3AA) results further tunes material properties: (FIG. 58A) Degradation in simulated tear fluid, demonstrating X3AA’s favorable biphasic mass loss profile, wherein materials remain stable within the treatment window followed by rapid degradation and elimination. (FIG. 58B) Enhanced swelling ratio of X3AA materials, favorable for continuous anchorage within the tear duct throughout the treatment window (inset shows significant volume swelling of X3AA, grid squares are 6mm x 6mm). (FIG. 58C) Maintenance of physiological pH during material degradation. FIGs. 59A, 59B, 59C, 59D, and 59E show that incorporation of riboflavin enhances fluorescent imaging of X3AA: (FIG. 59A) Structure of X3AA Rib polymer, showing conjugation of riboflavin into X3AA via esterification with citric acid. (FIG. 59B) NIR absorbance of X3AA and X3AA Rib prepolymers, indicating riboflavin incorporation does not diminish absorbance. Fluorescence profiles of (FIG.59C) X3AA and (FIG. 39D) X3AA Rib prepolymers, demonstrating intrinsics band shifting (inset shows prepolymers under normal and UV light). (FIG. 59E) Comparison of maximum fluorescence intensity, indicating X3AA Rib’s increased fluorescence (inset shows maximum excitation and emission wavelengths, demonstrating comparability with commercially utilized fluorescein dye. FIG. 60 depicts injection molding of sCUP-X3AA Riboflavin: Injection molded sCUPE-X3AA Rib thin films (~1cm x ~1cm), bulk pieces (~1cm x ~1cm), and intracanalicular implants, demonstrating significant green fluorescence. Attorney Docket No.11196-112WO1 FIG. 61 depicts Ex Vivo insertion of sCUPE-X3AA implants: Insertion of sCUPE- X3AA implants into rabbit tear duct, showing clear visibility even in the absence of fluorescence. FIG. 62 depicts an exemplary punctal plug design for implants: Punctal plug design incorporating a tapered design along with a larger diameter cap feature to prevent implant dislodgement as well as to improve visibility following implantation. FIG. 63 provides the glass transition temperature of X3 and X3AA without HDI crosslinking. Tg was measured using a TA instruments DSC in closed aluminum pans (sample size approximately 2 mg) at a heating rate of 10 °C / min. FIG. 64 provides the compressive strength and compressive modulus at 90% strain of X3 and X3AA both dry and wet for 24 hours. Compression testing was carried out on an Instron 5996 Testing Frame using polymer disks approximately 6 mm diameter x 3 mm height to 90% strain at 1.3 mm / min. Wet testing was carried out as above following incubation of samples in simulated tear fluid for 24 hours at 37 °C with shaking. Implants have complete recovery following compression to 90% in dry condition. FIG.65 depicts the X3 compression test at 90% strain. FIG.66 depicts the X3AA compression test to 90% strain. FIG. 67 provides the glass transition temperature of X3 and X3AA with HDI crosslinking. X3 and X3AA with and without HDI have a glass transition temperature between room temperature (25C) and body temperature (37C), which can be used for shape memory, wherein the implant has an initial shape at room temperature then adopts a secondary shape when heated by the body. This can be used to change the dimensions of the implant following implantation to lodge or anchor the implant in the duct, similar to the effect of swelling. This, combined with the above mechanical recover, suggests implants can be fixed in a compressed state then expand following implantation to lodge in the tear duct. FIG.68 depicts shape memory based tissue anchorage of the disclosed implants. FIG. 69 provides X33D fluorescence spectra and representative fluorescence of an X3 film. FIG. 70 provides X3 fluorescence excitation and emission spectra, photostability, and fluorescence properties. Fluorescence properties of solid films were measured on a Attorney Docket No.11196-112WO1 HORIBA Fluoromax4 to obtain 3D spectra, maximum excitation / emission and photostability (determined using constant irradiation at the max excitation and emission for 3 hours). Photostability indicates that the implant can be effectively visualized over extended time periods without photobleaching. FIG. 71 depicts Bromfenac release in ug / mL for B10 and B20 polymers. B10 = sX3AA polymer (crosslinked with HDI (1:1 mole ratio to X3AA prepolymer) with 10wt% Bromfenac mixed into prepolymer. B20 = sX3AA polymer (crosslinked with HDI (1:1 mole ratio to X3AA prepolymer) with 20wt% Bromfenac mixed into prepolymer. FIG.72 depicts Bromfenac release in ug / mg for B10 and B20 polymers. Like reference symbols in the various drawings indicate like elements. DETAILED DESCRIPTION The following description of the disclosure is provided as an enabling teaching of the disclosure in its best, currently known aspects. Many modifications and other aspects disclosed herein will come to mind to one skilled in the art to which the disclosed compositions and methods pertain, benefiting from the teachings presented in the descriptions herein and the associated drawings. Therefore, it is understood that the disclosures are not limited to the specific aspects disclosed and that modifications and other aspects are intended to be included within the scope of the appended claims. The skilled artisan will recognize many variants and adaptations of the aspects described herein. These variants and adaptations are intended to be included in the teachings of this disclosure and to be encompassed by the claims herein. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. As apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features that may be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or any other order that is logically possible. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not explicitly state Attorney Docket No.11196-112WO1 in the claims or descriptions that the steps are to be limited to a particular order, it is in no way intended that an order be inferred in any respect. This holds for any possible non- express basis for interpretation, including logic concerning arrangement of steps or operational flow, meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification. All publications mentioned herein are incorporated by reference to disclose and describe the methods or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure before the filing date of the present application. Further, the dates of publication provided herein can be different from the actual publication dates, which can require independent confirmation. It is also to be understood that the terminology herein describes particular aspects only and is not intended to be limiting. Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed compositions and methods belong. It can be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly defined herein. Before describing the various aspects of the present disclosure, the following definitions are provided and should be used unless otherwise indicated. Additional terms may be defined elsewhere in the present disclosure. Definitions As used herein, “comprising” is interpreted as specifying the presence of the stated features, integers, steps, or components but does not preclude the presence or addition of one or more features, integers, steps, components, or groups thereof. Moreover, each of the terms “by,” “comprising,” “comprises,” “comprised of,” “including,” “includes,” “included,” “involving,” “involves,” “involved,” and “such as” are used in their open, non- limiting sense and may be used interchangeably. Further, the term “comprising” is intended to include examples and aspects encompassed by the terms “consisting essentially of” and “consisting of.” Similarly, “consisting essentially of” is intended to include examples encompassed by the term “consisting of.” Attorney Docket No.11196-112WO1 As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context dictates otherwise. Ratios, concentrations, amounts, and other numerical data can be expressed herein in a range format. Further, the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. There are many values disclosed herein, and each value is also disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Ranges can be expressed herein as from “about” one particular value and to “about” another particular value. Similarly, when values are expressed as approximations, using the antecedent “about,” the particular value forms a further aspect. For example, if the value “about 10” is disclosed, then “10” is also disclosed. When a range is expressed, a further aspect includes from the one particular value and to the other particular value. For example, where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g., the phrase “x to y” includes the range from ‘x’ to ‘y’ as well as the range greater than ‘x’ and less than ‘y’. The range can also be expressed as an upper limit, e.g. ‘about x, y, z, or less’ and should be interpreted to include the specific ranges of ‘about x,’ ‘about y,’ and ‘about z’ as well as the ranges of ‘less than x,’ ‘less than y.’ and ‘less than z.’ Likewise, the phrase ‘about x, y, z, or greater’ should be interpreted to include the specific ranges of ‘about x,’ ‘about y,’ and ‘about z’ as well as the ranges of ‘greater than x,’ greater than y,’ and ‘greater than z.’ In addition, the phrase “about ‘x’ to ‘y’,” where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’.” Such a range format is used for convenience and brevity and thus, should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a numerical range of “about 0.1% to 5%” should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., about 1%, about 2%, about 3%, and about 4%) and the sub-ranges (e.g., about 0.5% to about 1.1%; about 5% to about 2.4%; about 0.5% to about 3.2%, and about 0.5% to about 4.4%, and other possible sub-ranges) within the indicated range. Attorney Docket No.11196-112WO1 As used herein, the terms “about,” “approximate,” “at or about,” and “substantially” mean that the amount or value in question can be the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein. That is, amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact but may be approximate, larger or smaller, as desired, reflecting tolerances, conversion factors, rounding, measurement error, and the like, and other factors known to those of skill in the art such that equivalent results or effects are obtained. In some circumstances, the value that provides equivalent results or effects cannot be reasonably determined. In such cases, as used herein, “about” and “at or about” mean the nominal value indicated ±10% variation unless otherwise indicated or inferred. In general, an amount, size, formulation, parameter, or other quantity or characteristic is “about,” “approximate,” or “at or about,” whether or not expressly stated to be such. Where “about,” “approximate,” or “at or about” is used before a quantitative value, the parameter also includes the specific quantitative value itself unless expressly stated otherwise. As used herein, the term “therapeutically effective amount” refers to an amount sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms but generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the particular compound employed and like factors within the knowledge and expertise of the health practitioner and which may be well known in the medical arts. In the case of treating a particular disease or condition, in some instances, the desired response can be inhibiting the progression of the disease or condition. This may involve only slowing the progression of the disease temporarily. However, in other instances, it may be desirable to permanently halt the progression of the disease. This can be monitored by routine diagnostic methods known to one of ordinary skill in the art for any particular disease. The desired response to treatment of the disease or condition can also be delaying the onset or even preventing the onset. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to increase the Attorney Docket No.11196-112WO1 dosage gradually until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The individual physician can adjust the dosage in the event of any contraindications. It is generally preferred that a maximum dose of the pharmacological agents of the disclosure (alone or in combination with other therapeutic agents) be used, that is, the highest safe dose according to sound medical judgment. However, a patient may insist on a lower or tolerable dose for medical reasons, psychological reasons, or virtually any other reason. A response to a therapeutically effective dose of a disclosed compound or composition can be measured by determining the physiological effects of the treatment or medication, such as the decrease or lack of disease symptoms following the administration of the treatment or pharmacological agent. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response. The amount of a treatment may be varied, for example, by increasing or decreasing the amount of a disclosed compound or pharmaceutical composition, changing the disclosed compound or pharmaceutical composition administered, changing the route of administration, changing the dosage timing, and so on. Dosage can vary and can be administered in one or more dose administrations daily for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. As used herein, the term “prophylactically effective amount” refers to an amount effective for preventing the onset or initiation of a disease or condition. As used herein, “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. Where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. As used herein, “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur. The description includes instances where said event or circumstance occurs and those where it does not. As used interchangeably herein, “subject,” “individual,” or “patient” can refer to a vertebrate organism, such as a mammal (e.g., human). “Subject” can also refer to a cell, a population of cells, a tissue, an organ, or an organism, preferably to a human and constituents thereof. Attorney Docket No.11196-112WO1 As used herein, “treating” and “treatment” generally refer to obtaining a desired pharmacological or physiological effect. The effect can be but does not necessarily have to be prophylactic in preventing or partially preventing a disease, symptom, or condition. The effect can be therapeutic regarding a partial or complete cure of a disease, condition, symptom, or adverse effect attributed to the disease, disorder, or condition. The term “treatment” as used herein can include any treatment of a disorder in a subject, particularly a human. It can include any one or more of the following: (a) preventing the disease from occurring in a subject who may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease or its symptoms or conditions. The term “treatment,” as used herein, can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment. Those in need of treatment (i.e., subjects in need thereof) can include those already with the disorder or those in which the disorder is to be prevented. As used herein, the term “treating” can include inhibiting the disease, disorder, or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder, or condition. Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, e.g., such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain. As used herein, “dose,” “unit dose,” or “dosage” can refer to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of a disclosed compound or a pharmaceutical composition thereof calculated to produce the desired response or responses in association with its administration. As used herein, “therapeutic” can refer to treating, healing, or ameliorating a disease, disorder, condition, or side effect or decreasing the rate of advancement of a disease, disorder, condition, or side effect. The term “therapeutic agent” includes any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to an organism (either human or a nonhuman animal), induces a desired pharmacologic, immunogenic, and / or physiologic effect by local and / or systemic action. The term therefore encompasses those compounds or chemicals traditionally regard as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, Attorney Docket No.11196-112WO1 gene constructs and the like. Examples of therapeutic agents are described in well-known literature references such as the Merk Index (14thEdition), the Physician’s Desk Reference (64thEdition), and The Pharmacological Basis of Therapeutics (12thEdition), and they include, without limitation, medicaments; vitamins; mineral supplements, substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. For example, the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti- inflammatory agents, anti-epileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants, anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiandrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics, antispasmodics, cardiovascular preparations (including calcium channel blockers, beta blockers, and beta-agonists), antihypertensives, diuretics, vasodilators, central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, bone growth stimulants and bone resorption inhibitors, immunosuppressives, muscle relaxants, psychostimulants, sedatives, tranquilizers, proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced), and nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including both double and single-stranded molecules, gene constructs, expression vectors, antisense molecules and the like), small molecules and other biologically active macromolecules such as, for examples, proteins and enzymes. The agent may be a biologically active agent used in medical, including veterinary, applications and in agriculture, such as with plants, as well as other areas. As used herein, the term or phrase “effective,” “effective amount,” or “conditions effective to” refers to such amount or condition that is capable of performing the function or property for which an effective amount or condition is expressed. As will be pointed out below, the exact amount or particular condition required will vary from one aspect to another, depending on recognized variables such as the materials employed and the Attorney Docket No.11196-112WO1 processing conditions observed. Thus, it is not always possible to specify an exact “effective amount” or “condition effective to.” However, it should be understood that an appropriate effective amount will be readily determined by one of ordinary skill in the art using only routine experimentation. Although the operations of exemplary aspects of the disclosed method may be described in a particular sequential order for convenient presentation, it should be understood that disclosed aspects can encompass an order of operations other than the particular sequential order disclosed. For example, operations described sequentially may, in some cases, be rearranged or performed concurrently. Further, descriptions and disclosures provided in association with one particular aspect are not limited to that aspect and may be applied to any aspect disclosed. The terms “coupled” and “associated” generally mean electrically, electromagnetically, and / or physically (e.g., mechanically or chemically) coupled or linked and do not exclude the presence of intermediate elements between the coupled or associated items. It will be understood that when an element is referred to as being "connected" or "coupled" to another element, it can be directly connected or coupled to the other element, or intervening elements can be present. In contrast, when an element is referred to as being "directly connected" or "directly coupled" to another element, there are no intervening elements present. Other words used to describe the relationship between elements or layers should be interpreted in a like fashion (e.g., "between" versus "directly between," "adjacent" versus "directly adjacent," "on" versus "directly on"). It will be understood that although the terms "first," "second," etc., can be used herein to describe various elements, components, regions, layers and / or sections. These elements, components, regions, layers, and / or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or a section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of example aspects. Spatially relative terms, such as,“ "beneath," "below," "lower," "above," "upper," “upward,” “downward,” “top,” “bottom,” and the like, can be used herein for ease of description to describe one element or feature's relationship to another element(s) or Attorney Docket No.11196-112WO1 feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as "below" or "beneath" other elements or features would then be oriented "above" the other elements or features. Thus, the term "below" can encompass both an orientation of above and below. The device can be otherwise oriented (rotated 90 degrees or at other orientations), and the spatially relative descriptors used herein are interpreted accordingly. Terms such as “proximal,” “distal,” “ radially outward,” “radially inward,” “outer,” “inner,” and “side” describe the orientation and / or location of portions of the components or elements within a consistent but arbitrary frame of reference which is made clear by reference to the text and the associated drawings describing the components or elements under discussion. Such terminology can include the words specifically mentioned above, derivatives thereof, and words of similar import. Similarly, the terms “first,” “second,” and other such numerical terms referring to structures neither imply a sequence nor order unless clearly indicated by the context. As used herein, the term "substantially" means that the subsequently described event or circumstance completely occurs or that the subsequently described event or circumstance generally, typically, or approximately occurs. Still further, the term “substantially” can, in some aspects, refer to at least about 90 %, at least about 91 %, at least about 92 %, at least about 93 %, at least about 94 %, at least about 95 %, at least about 96 %, at least about 97 %, at least about 98 %, at least about 99 %, or about 100 % of the stated property, component, composition, or other condition for which substantially is used to characterize or otherwise quantify an amount. As used herein, the term “substantially,” in, for example, the context “substantially identical” or “substantially similar,” refers to a method or a system, or a component that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% by similar to the method, system, or the component it is compared to. Chemical Definitions Attorney Docket No.11196-112WO1 Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs. The compounds described herein include enantiomers, mixtures of enantiomers, diastereomers, tautomers, racemates and other isomers, such as rotamers, as if each is specifically described, unless otherwise indicated or otherwise excluded by context. It is to be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration. The compounds provided herein may either be enantiomerically pure or be diastereomeric or enantiomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. As such, one of skill in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form. Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture. Compounds described herein may contain one or more double bonds and, thus, potentially give rise to cis / trans (E / Z) isomers, as well as other conformational isomers. Unless states to the contrary, all such possible isomers are contemplated, as well as mixtures of such isomers. Compounds described herein may also present as an equilibrium of tautomers. For example, ketones with an α-hydrogen can exist in an equilibrium of the keto form and the enol form. Likewise, amides with an N-hydrogen can exist in an equilibrium of the amide form and the imidic acid form. Unless stated to the contrary, all possible tautomers of the compounds described herein are contemplated. A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for For example, -(C=O)NH2 is attached through the carbon of the keto (C=O) group. The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a moiety selected from the indicated group, provided that the designated atom’s normal valence is not exceeded and the resulting compound is stable. For example, when the substituent is oxo (i.e., =O) then two hydrogens Attorney Docket No.11196-112WO1 on the atom are replaced. For example, a pyridyl group substituted by oxo is a pyridine. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable active compound refers to a compound that can be isolated and / or can be formulated into a form with a shelf life of at least one month. A stable manufacturing intermediate or precursor to an active compound is stable if it does not degrade within the period needed for reaction or other use. A stable moiety or substituent group is one that does not degrade, react or fall apart within the period necessary for use. Non-limiting examples of unstable moieties are those that combine heteroatoms in an unstable arrangement, as typically known and identifiable to those of skill in the art. Any suitable group may be present on a “substituted” or “optionally substituted” position that forms a stable molecule and meets the desired purpose of the disclosure and includes, but is not limited to: halo, nitro, cyano, azido, oxo, C1-C6alkyl, C1-C6haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C3-C6 cycloalkyl)(C0-C3 alkyl)-, (3- to 8-membered monocyclic or bicyclic heterocycle)-(C0-C6alkyl)-, (6- to 10-membered monocyclic or bicyclic aryl)-(C0-C6 alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C6 alkyl)-, AxO-(C0-C6 alkyl)-, AxS-(C0-C6 alkyl)-, (AxAyN)-(C0-C6 alkyl)-, AzC(O)-(C0-C6 alkyl)-, AzC(N)-(C0-C6 alkyl)-, and AzS(O)-(C0-C6 alkyl)-, and AzS(O)2-(C0-C6 alkyl)-, wherein Axand Ayare independently selected at each occurrence from Aa, AzC(O)-, AzC(N)- , AzS(O)-, and AzS(O)2-, each of which may be optionally substituted with one or more B groups as allowed by valency; wherein Azis independently selected at each occurrence from hydrogen, halo, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)- (C0-C3 alkyl)-, (4- to 6-membered heterocycle)-(C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic aryl)-(C0-C3alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, -OAa, -SAa, and -NAaAb, each of which may be optionally substituted with one or more B groups as allowed by valency; wherein Aaand Abare independently selected at each occurrence from hydrogen, C1-C6alkyl, C1-C6haloalkyl, C2- C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)-(C0-C3alkyl)-, (4- to 6-membered heterocycle)- (C0-C3 alkyl)-, (5- to 10-membered monocyclic or bicyclic aryl)-(C0-C3 alkyl)-, (5- to 10- membered monocyclic or bicyclic heteroaryl)-(C0-C3 alkyl)-, each of which may be optionally substituted by one or more B groups as allowed by valency; and wherein B is independently selected at each occurrence from hydrogen, halo, nitro, cyano, azido, oxo, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C6cycloalkyl)(C0-C3alkyl)- Attorney Docket No.11196-112WO1 , (3- to 8-membered monocyclic or bicyclic heterocycle)-(C0-C6alkyl)-, (6- to 10- membered monocyclic or bicyclic aryl)-(C0-C6alkyl)-, (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C6 alkyl)-, ApO-, ApS-, ApAqN-, AoC(O)-, AoC(O)-O-, AoC(O)-NAq- , AoS(O)2-, AoS(O)2-O-, and AoS(O)2-NAq-, wherein Aois independently selected at each occurrence from Ap, halo, ApO-, and ApAqN-, and wherein Apand Aqare independently selected at each occurrence from hydrogen, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2- C6 alkynyl, (C3-C6 cycloalkyl)(C0-C3 alkyl)-, (3- to 8-membered monocyclic or bicyclic heterocycle)-(C0-C6alkyl)-, (6- to 10-membered monocyclic or bicyclic aryl)-(C0-C6alkyl)-, and (5- to 10-membered monocyclic or bicyclic heteroaryl)-(C0-C6 alkyl)-. The terms for various functional groups as used herein are not intended to be limited to monovalent radicals and may include polyvalent radical groups as appropriate, such as divalent, trivalent, tetravalent, pentavalent, and hexavalent groups, and the like, based on the position and location of such groups in the compounds described herein as would be readily understood by the skilled person in the context in which said functional groups are recited. As used herein, the symbol “ ” (which hereinafter can be referred to as “a point of attachment bond”) denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond. For example, “ ” indicates that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond. Furthermore, the specific point of attachment to the non-depicted chemical entity can be specified by inference. For example, the compound CH3-R3, wherein R3is H or “ ” infers that when R3is “XY”, the point of attachment bond is the same bond as the bond by which R3is depicted as being bonded to CH3. “Halo” or “halogen” indicates, independently, any of fluoro, chloro, bromo or iodo. The term “nitro” as used herein is represented by the formula —NO2. The term “cyano” as used herein is represented by the formula —CN The term “azido” as used herein is represented by the formula –N3. The term “oxo” as used herein is represented by the formula =O. Attorney Docket No.11196-112WO1 “Alkyl” is a straight chain or branched saturated aliphatic hydrocarbon group. In certain aspects, the alkyl is C1-C2, C1-C3, or C1-C6(i.e., the alkyl chain can be 1, 2, 3, 4, 5, or 6 carbons in length). The specified ranges as used herein indicate an alkyl group with length of each member of the range described as an independent species. For example, C1- C6alkyl as used herein indicates an alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species and C1- C4alkyl as used herein indicates an alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. When C0- Cnalkyl is used herein in conjunction with another group, for example (C3-C7cycloalkyl)C0- C4alkyl, or -C0-C4(C3-C7cycloalkyl), the indicated group, in this case cycloalkyl, is either directly bound by a single covalent bond (C0alkyl), or attached by an alkyl chain, in this case 1, 2, 3, or 4 carbon atoms. Alkyls can also be attached via other groups such as heteroatoms, as in -O-C0-C4alkyl(C3-C7cycloalkyl). Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2- dimethylbutane, and 2,3-dimethylbutane. In some aspects, the alkyl group is optionally substituted as described herein. “Haloalkyl” refers to an alkyl group that is substituted with one or more halo groups, e.g., fluoro, chloro, bromo, iodo, or combinations thereof. “Cycloalkyl” is a saturated or partially unsaturated mono- or multi-cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused or bridged fashion. Non-limiting examples of typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. In some aspects, the cycloalkyl group is optionally substituted as described herein. “Alkenyl” is a straight or branched chain aliphatic hydrocarbon group having one or more carbon-carbon double bonds, each of which is independently either cis or trans, that may occur at a stable point along the chain. Non-limiting examples include C2-C4alkenyl and C2-C6alkenyl (i.e., having 2, 3, 4, 5, or 6 carbons). The specified ranges as used herein indicate an alkenyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkenyl include, but are not limited to, ethenyl and propenyl. In one aspect, the alkenyl group is optionally substituted as described herein. Attorney Docket No.11196-112WO1 “Alkynyl” is a straight or branched chain aliphatic hydrocarbon group having one or more carbon-carbon triple bonds that may occur at any stable point along the chain, for example, C2-C4alkynyl or C2-C6alkynyl (i.e., having 2, 3, 4, 5, or 6 carbons). The specified ranges as used herein indicate an alkynyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, and 5-hexynyl. In one aspect, the alkynyl group is optionally substituted as described herein. “Aryl” indicates an aromatic group containing only carbon in the aromatic ring or rings. In one aspect, the aryl group contains 1 to 3 separate or fused rings and is 6 to 14 or 18 ring atoms, without heteroatoms as ring members. When indicated, such aryl groups may be further substituted with carbon or non-carbon atoms or groups. Such substitution may include fusion to a 4- to 7- or 5- to 7-membered saturated or partially unsaturated cyclic group that optionally contains 1, 2, or 3 heteroatoms independently selected from N, O, B, P, Si and S, to form, for example, a 3,4-methylenedioxyphenyl group. Aryl groups include, for example, phenyl and naphthyl, including 1-naphthyl and 2-naphthyl. In one aspect, aryl groups are pendant. An example of a pendant ring is a phenyl group substituted with a phenyl group. In one aspect, the aryl group is optionally substituted as described herein. The term “heterocycle” refers to saturated and partially saturated heteroatom- containing ring radicals, where the heteroatoms may be selected from N, O, and S. The term heterocycle includes monocyclic 3-12 members rings, as well as bicyclic 5-16 membered ring systems (which can include fused, bridged, or spiro bicyclic ring systems). It does not include rings containing -O-O-, -O-S-, and -S-S- portions. Examples of saturated heterocycle groups including saturated 4- to 7-membered monocyclic groups containing 1 to 4 nitrogen atoms [e.g., pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, azetidinyl, piperazinyl, and pyrazolidinyl]; saturated 4- to 6-membered monocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g., morpholinyl]; and saturated 3- to 6- membered heteromonocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl]. Examples of partially saturated heterocycle radicals include, but are not limited, dihydrothienyl, dihydropyranyl, dihydrofuryl, and dihydrothiazolyl. Examples of partially saturated and saturated heterocycle groups include, but are not limited to, pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, Attorney Docket No.11196-112WO1 morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro- benzo[1,4]dioxanyl, indolinyl, isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3,4- tetrahydro-quinolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4- triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, benzo[1,4]dioxanyl, 2,3,- dihydro-1H-benzo[d]isothazol-6-yl, dihydropyranyl, dihydrofuryl, and dihydrothiazolyl. Bicyclic heterocycle includes groups wherein the heterocyclic radical is fused with an aryl radical wherein the point of attachment is the heterocycle ring. Bicyclic heterocycle also includes heterocyclic radicals that are fused with a carbocyclic radical. Representative examples include, but are not limited to, partially unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, for example indoline and isoindoline, partially unsaturated condensed heterocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, partially unsaturated condensed heterocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, and saturated condensed heterocyclic groups containing 1 to 2 oxygen or sulfur atoms. In one aspect, the heterocycle group is optionally substituted as described herein. “Heteroaryl” refers to a stable monocyclic, bicyclic, or multicyclic aromatic ring which contains from 1 to 4, or in some aspects 1, 2, or 3 heteroatoms selected from N, O, S, B, and P (and typically selected from N, O, and S) with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5, 6, or 7 membered aromatic ring which contains from 1 to 4, or in some aspects from 1 to 3 or from 1 to 2, heteroatoms selected from N, O, S, B, or P, with remaining ring atoms being carbon. In one aspect, the only heteroatom is nitrogen. In one aspect, the only heteroatom is oxygen. In one aspect, the only heteroatom is sulfur. Monocyclic heteroaryl groups typically have from 5 to 6 ring atoms. In some aspects, bicyclic heteroaryl groups are 8- to 10-membered heteroaryl groups, that is groups containing 8 or 10 ring atoms in which one 5-, 6-, or 7-membered aromatic ring which contains from 1 to 4 heteroatoms selected from N, O, S, B, or P is fused to a second aromatic or non-aromatic ring, wherein the point of attachment is an aromatic ring. When the total number of S and O atoms in the heteroaryl ring exceeds 1, these heteroatoms are not adjacent to one another within the ring. In one aspect, the total number of S and O atoms in the heteroaryl ring is not more than 2. In another aspect, the total number of S and O atoms in the heteroaryl ring is not more than 1. Examples of heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, Attorney Docket No.11196-112WO1 pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. In one aspect, the heteroaryl group is optionally substituted as described herein. A “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, pharmaceutically acceptable, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include salts which are acceptable for human consumption and the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic salts. Example of such salts include, but are not limited to, those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH2)1-4-COOH, and the like, or using a different acid that produced the same counterion. Suitable counterions found in pharmaceutically acceptable salts described herein include, but are not limited to, cations such as calcium, chloroprocaine, choline, diethanolamine, ethanolamine, ethylenediamine, meglumine, Attorney Docket No.11196-112WO1 potassium, procaine, sodium, triethylamine, and zinc, and anions such as acetate, aspartate, benzenesulfonate, besylate, bicarbonate, bitartrate, bromide, camsylate, carbonate, chloride, citrate, decanoate, edetate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolate, hexanoate, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, octanoate, oleate, pamoate, pantothenate, phosphate, polygalacturonate, propionate, salicylate, stearate, succinate, sulfate, tartrate, teoclate, and tosylate. Lists of additional suitable salts may be found, e.g., in Remington’s Pharmaceutical Sciences, 17thed., Mack Publishing Company, Easton, PA., p.1418 (1985). As used herein, the term “derivative” refers to a compound having a structure derived from the structure of a parent compound (e.g., a compound disclosed herein) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compound. Exemplary derivatives include, but are not limited to, salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound. Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art. For example, the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers, such as Sigma-Aldrich (formally MilliporeSigma, Burlington, MA) or Thermo Fisher Scientific Inc. (Waltham, MA), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis (John Wiley and Sons, 2007); Organic Reactions (John Wiley and Sons, 2004); March's Advanced Organic Chemistry, (John Wiley and Sons, 8thEdition); and Larock's Comprehensive Organic Transformations (John Wiley and Sons, 3rdedition, 2017). The present disclosure also includes compounds described herein with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, Attorney Docket No.11196-112WO1 and chlorine, such as2H,3H,11C,13C,15N,17O,18O,18F,31P, 32P,35S,36Cl, and125I, respectively. In one aspect, isotopically labeled compounds can be used in metabolic studies (with14C), reaction kinetic studies (with, for example2H or3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug and substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an18F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed herein by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent. By way of general example and without limitation, isotopes of hydrogen, for example deuterium (2H) and tritium (3H) may optionally be used anywhere in described structures that achieves the desired result. Alternatively, or in addition, isotopes of carbon, e.g.,13C and14C, may be used. In one aspect, the isotopic substitution is replacing hydrogen with a deuterium at one or more locations on the molecule to improve the performance of the molecule as a drug, for example, the pharmacodynamics, pharmacokinetics, biodistribution, half-life, stability, AUC, Tmax, Cmax, etc. For example, the deuterium can be bound to carbon in allocation of bond breakage during metabolism (an alpha-deuterium kinetic isotope effect) or next to or near the site of bond breakage (a beta-deuterium kinetic isotope effect). Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain aspects, the isotope is 80, 85, 90, 95, or 99% or more enriched in an isotope at any location of interest. In some aspects, deuterium is 80, 85, 90, 95, or 99% enriched at a desired location. Unless otherwise stated, the enrichment at any point is above natural abundance, and in an aspect is enough to alter a detectable property of the compounds as a drug in a human. The compounds of the present disclosure may form a solvate with solvents (including water). Therefore, in one aspect, the disclosure includes a solvated form of the active compound. The term “solvate” refers to a molecular complex of a compound of the present disclosure (including a salt thereof) with one or more solvent molecules. Non- limiting examples of solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents. The term “hydrate” refers to a molecular complex comprising a Attorney Docket No.11196-112WO1 disclosed compound and water. Pharmaceutically acceptable solvates in accordance with the disclosure include those wherein the solvent of crystallization may be isotopically substituted, e.g., D2O, d6-acetone, or d6-DMSO. A solvate can be in a liquid or solid form. A “prodrug” as used herein means a compound which when administered to a host in vivo is converted into a parent drug. As used herein, the term “parent drug” means any of the presently described compounds herein. Prodrugs can be used to achieve any desired effect, including to enhance properties of the parent drug or to improve the pharmaceutic or pharmacokinetic properties of the parent, including to increase the half-life of the drug in vivo. Prodrug strategies provide choices in modulating the conditions for in vivo generation of the parent drug. Non-limiting examples of prodrug strategies include covalent attachment of removable groups, or removable portions of groups, for example, but not limited to, acylating, phosphorylation, phosphonylation, phosphoramidate derivatives, amidation, reduction, oxidation, esterification, alkylation, other carboxy derivatives, sulfoxy or sulfone derivatives, carbonylation, or anhydrides, among others. In certain aspects, the prodrug renders the parent compound more lipophilic. In certain aspects, a prodrug can be provided that has several prodrug moieties in a linear, branched, or cyclic manner. For example, non- limiting aspects include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent compound with another prodrug moiety and is typically biodegradable in vivo. In some aspects, 2, 3, 4, or 5 prodrug biodegradable moieties are covalently bound in a sequence, branched, or cyclic fashion to the parent compound. Non-limiting examples of prodrugs according to the present disclosure are formed with: a carboxylic acid on the parent drug and a hydroxylated prodrug moiety to form an ester; a carboxylic acid on the parent drug and an amine prodrug to form an amide; an amino on the parent drug and a carboxylic acid prodrug moiety to form an amide; an amino on the parent drug and a sulfonic acid to form a sulfonamide; a sulfonic acid on the parent drug and an amino on the prodrug moiety to form a sulfonamide; a hydroxyl group on the parent drug and a carboxylic acid on the prodrug moiety to form an ester; a hydroxyl on the parent drug and a hydroxylated prodrug moiety to form an ester; a phosphonate on the parent drug and a hydroxylated prodrug moiety to form a phosphonate ester; a phosphoric acid on the parent drug and a hydroxylated prodrug moiety to form a phosphate ester; a hydroxyl on the parent drug and a phosphonate on the prodrug to form a phosphonate ester; a hydroxyl on the parent drug and a phosphoric acid prodrug moiety to Attorney Docket No.11196-112WO1 form a phosphate ester; a carboxylic acid on the parent drug and a prodrug of the structure HO-(CH2)2-O-(C2-24alkyl) to form an ester; a carboxylic acid on the parent drug and a prodrug of the structure HO-(CH2)2-S-(C2-24 alkyl) to form a thioester; a hydroxyl on the parent drug and a prodrug of the structure HO-(CH2)2-O-(C2-24alkyl) to form an ether; a hydroxyl on the parent drug and a prodrug of the structure HO-(CH2)2-O-(C2-24 alkyl) to form an thioether; and a carboxylic acid, oxime, hydrazide, hydrazine, amine or hydroxyl on the parent compound and a prodrug moiety that is a biodegradable polymer or oligomer including but not limited to polylactic acid, polylactide-co-glycolide, polyglycolide, polyethylene glycol, polyanhydride, polyester, polyamide, or a peptide. In some aspects, a prodrug is provided by attaching a natural or non-natural amino acid to an appropriate functional moiety on the parent compound, for example, oxygen, nitrogen, or sulfur, and typically oxygen or nitrogen, usually in a manner such that the amino acid is cleaved in vivo to provide the parent drug. The amino acid can be used alone or covalently linked (straight, branched or cyclic) to one or more other prodrug moieties to modify the parent drug to achieve the desired performance, such as increased half-life, lipophilicity, or other drug delivery or pharmacokinetic properties. The amino acid can be any compound with an amino group and a carboxylic acid, which includes an aliphatic amino acid, alkyl amino acid, aromatic amino acid, heteroaliphatic amino acid, heteroalkyl amino acid, heterocyclic amino acid, or heteroaryl amino acid. This disclosure provides an implant formed from a biodegradable polymer or oligomer composed primarily of citric acid, xylitol, and octanediol (citrate-xylitol) designed to be inserted into the eye or adjacent tear ducts or tissues in a minimally invasive fashion followed by a period of residence during which the implant releases a therapeutic agent. Further, at a desired time post-implantation, the implant is completely degraded, terminating treatment without implant removal. This disclosure provides dropless post-surgery cataract care. The small, biodegradable, painless intracanalicular implant combines the anti-inflammatory and antibacterial properties of citrate-xylitol with the leading anti-inflammatory ocular therapeutic, Bromfenac, to grant patients freedom from administering eye drops post- surgery. The drug-eluting implant, upon placement, swells to fit securely and comfortably within the canaliculus. The implant administers anti-inflammatory and anti-bacterial treatment over a period of at least 30 days while it slowly dissolves, leaving no implant that requires removal or permanent residence in the patient. Attorney Docket No.11196-112WO1 Existing alternatives to eye drops suffer from a high inflammation breakthrough rate (10%), resulting in the need for rescue eye drops, and further do not provide the intrinsic advantages of fluorescent / photoacoustic implant tracking, photothermal capability, anti- oxidant and anti-microbial potential, or highly tunable material properties embodied in the citrate-xylitol material family. The disclosed materials / implants have potential additional applications including treatment of conditions including general, post-surgical inflammation and infection, glaucoma, ocular hypertension, age associated macular degeneration, dry eye disease, and diabetic retinopathy as a platform material system for ophthalmic therapy. Recently, a family of highly versatile biomaterials based on citric acid has been developed for multiple applications including drug delivery and cardiac, orthopedic, and soft tissue regeneration, culminating in the FDA approval of citrate-based ACL screws. Citrate, well known for its canonical role in the metabolic cycle, has emerged as a potent multifunctional monomer for polymer synthesis. Through a series of simple catalyst free reactions, crosslinked citrate-based elastomers (CBEs), typified by poly(octamethylene citrate) (POC), have been synthesized. POC, as well as its constituent monomers, citric acid and octanediol, have been shown to be biocompatible both in vitro and in vivo, with excellent blood and tissue compatibility, and minimal inflammatory response. POC is also highly tunable through modification both during and post-polymerization, resulting in a wide range of materials including biodegradable photoluminescent polymers (BPLPs), injectable poly(alkylene maleate citrate) (PAMC) and mussel inspired bioadhesives (iCMBA). CBEs present tunable properties including mechanics, degradation rates (days to > 1 year), and swelling ratios, and are readily fabricated into films, porous scaffolds, and tubes. Additionally, citrate imparts both antimicrobial and anti-inflammatory properties; however, CBEs still suffer from low mechanical strengths and long degradation times (36 weeks for POC). The creation of biomaterials capable of highly tunable mechanical strengths and rapid degradation is a critical challenge. Previous CBEs such as POC have failed in this regard, thus requiring a new approach through polymer network engineering. High strength crosslinked materials are typically achieved through the maximization of crosslink density; however, this will typically be countered by a large decrease in degradation rate without careful selection of the desired monomer. Xylitol, a five carbon pentanol, was duly chosen as a crosslink density enhancer due to its five reactive hydroxyl groups liable to polycondensation with citrate. Critically, xylitol is a hydrophilic, water-soluble monomer, Attorney Docket No.11196-112WO1 capable of enhancing water uptake and thus hydrolysis of ester bonds in CBE networks, increasing degradation. Additionally, increased water uptake results in significant swelling and expansion upon contact with fluid, anchoring the material in the surrounding tissue. Further, abundant preserved hydroxyl groups serve both as reaction sites for direct esterification with carboxyl groups present on bromfenac and as hydrogen bonding moieties capable of extending drug release through both covalent and H-bond interactions. Finally, the highly branched and hydrogen bonded network results in significant intra- and intermolecular π-π*and n-σ*interactions between carbonyl and hydroxyl groups, resulting in significant and broad fluorescence. Thus, a new class of citrate / xylitol-based elastomers (CXBEs) engineered to achieve high crosslink density, combining highly tunable mechanical properties, accelerated degradation, extended drug release, intrinsic fluorescence, and increased swelling-based anchoring was designed as a material for intracanalicular implants. Ocular Implants and Polymers / Oligomers In one aspect, the present disclosure provides ocular implants. In some aspects, the ocular implants may comprise a polymer or oligomer. In some aspects, the polymer or oligomer is formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; and optionally one or more additional monomers. The ocular implant can be suitable for placement within or proximal to the eye. In some aspects, the ocular implant is suitable for placement within an intracanalicular duct. In other aspects, the ocular implant is suitable for placement within a scleral membrane. In further aspects, the ocular implant is suitable for placement into a subconjunctival position and / or a parabular position. In other aspects, the ocular implant is suitable for placement into an intravitreal environment. In some aspects, the citric acid can comprise citric acid or a citrate salt (such as sodium citrate, potassium citrate, calcium citrate, magnesium citrate, lithium citrate, or ammonium citrate). In some aspects, the citric acid can comprise an alkoxylated, alkenoxylated, or non-alkoxylated and non-alkenoxylated citric acid, citrate, or ester or amide of citric acid. In some aspects, the citric acid can comprise a citrate ester (such as triethyl citrate). In some aspects, the molar ratio of citric acid, or a salt or derivative thereof, to 1,8- octanediol and xylitol in the polymer or oligomer is from about 3:1 to about 1:3, including Attorney Docket No.11196-112WO1 exemplary values of about 3:1, 2.5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, or any subrange formed from the above exemplary values. In some aspects, the molar ratio of 1,8-octanediol to xylitol in the polymer or oligomer is from about 3:1 to about 1:3, including exemplary values of about 3:1, 2.5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, or any subrange formed from the above exemplary values. In some aspects, the optional one or more additional monomers may comprise ascorbic acid or a salt or derivative thereof. In some aspects, the optional one or more additional monomers may comprise an ascorbate salt (such as sodium ascorbate, calcium ascorbate, potassium ascorbate, or magnesium ascorbate). In some aspects, the optional one or more additional monomers may comprise an ascorbate ester (such as ascorbyl palmitate or ascorbyl stearate). In one aspect, a polymer or oligomer is provided formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; ascorbic acid, or a salt or derivative thereof; and optionally one or more additional monomers. In some aspects, the optional one or more additional monomers may comprise a catechol-containing species. The catechol containing species can comprise any catechol- containing species not inconsistent with the objects of the present disclosure. In some cases, a catechol-containing species comprises at least one moiety that can form an ester or amide bond with another chemical species used to form the polymer or oligomer. For example, in some aspects, a catechol-containing species comprises an alcohol moiety, an amine moiety, a carboxylic acid moiety, or combinations thereof. Further, in some aspects, a catechol- containing species comprises a hydroxyl moiety that is not part of the catechol moiety. In some aspects, a catechol-containing species comprises dopamine. In other aspects, a catechol-containing species comprises L-3,4-dihydroxyphenylalanine (L-DOPA) or D-3,4- dihydroxyphenylalanine (D-DOPA). In still other aspects, a catechol-containing species comprises gallic acid or caffeic acid. In some aspects, a catechol-containing species comprises 3,4-dihydroxycinnamic acid. Additionally, a catechol-containing species may also comprise a naturally-occurring species or a derivative thereof, such as tannic acid or a tannin. Moreover, in some aspects, a catechol-containing species is coupled to the backbone of the polymer or oligomer through an amide bond. In other aspects, a catechol-containing Attorney Docket No.11196-112WO1 species is coupled to the backbone of the polymer or oligomer through an ester bond. Further examples of catechol-containing species can be found in U.S. Patent Application Publication No. 2020 / 0140607 and International Patent Application Publication No. WO2018 / 227151, the contents of which are incorporated herein in their entirety. In some aspects, the one or more additional monomers may comprise dopamine, L-DOPA, D- DOPA, gallic acid, caffeic acid, 3,4-dihydroxyhydrocinnamic acid, and tannic acid. In some aspects, the optional one or more additional monomers may comprise a polycarboxylic acid, such as a dicarboxylic acid, or a functional equivalent of a polycarboxylic acid, such as a cyclic anhydride or an acid chloride of a polycarboxylic acid. In some aspects, the polycarboxylic acid or functional equivalent thereof can be saturated or unsaturated. In some aspects, for example, the polycarboxylic acid or functional equivalent thereof comprises maleic acid, maleic anhydride, fumaric acid, or fumaryl chloride. In some aspects, a vinyl-containing polycarboxylic acid or functional equivalent thereof may also be used, such as allylmalonic acid, allylmalonic chloride, itaconic acid, or itaconic chloride. Further, in some aspects, the polycarboxylic acid or functional equivalent thereof can be at least partially replaced with an olefin-containing monomer that may or may not be a polycarboxylic acid. In some aspects, for instance, an olefin-containing monomer comprises an unsaturated polyol such as a vinyl-containing diol. Further examples can be found in U.S. Patent Application Publication No.2020 / 0140607 and International Patent Application Publication No. WO2018 / 227151, the contents of which are incorporated herein in their entirety. In some aspects, the optional one or more additional monomers may comprise an amino acid, such as an alpha-amino acid. An alpha-amino acid as used herein, in some aspects, comprises an L-amino acid, a D-amino acid, or a D,L-amino acid. In some aspects, an alpha-amino acid comprises alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, proline, phenylalanine, serine, threonine, tyrosine, tryptophan, valine, or a combination thereof. Further, in some aspects, an alpha-amino acid comprises an alkyl-substituted alpha-amino acid, such as a methyl-substituted amino acid derived from any of the 22 “standard” or proteinogenic amino acids, such as methyl serine. In some aspects, the optional one or more additional monomers may comprise a fluorophore. Fluorophores are compounds or molecules that luminesce. Typically fluorophores absorb electromagnetic energy at one wavelength and emit electromagnetic Attorney Docket No.11196-112WO1 energy at a second wavelength. Representative fluorophores include, but are not limited to, 1,5 IAEDANS; 1,8-ANS; 4- Methylumbelliferone; 5-carboxy-2,7-dichlorofluorescein; 5- Carboxyfluorescein (5-FAM); 5-Carboxynapthofluorescein; 5- Carboxytetramethylrhodamine (5-TAMRA); 5-Hydroxy Tryptamine (5-HAT); 5-ROX (carboxy-X-rhodamine); 6-Carboxyrhodamine 6G; 6-CR 6G; 6-JOE; 7-Amino-4- methylcoumarin; 7-Aminoactinomycin D (7-AAD); 7-Hydroxy-4- I methylcoumarin; 9- Amino-6-chloro-2-methoxyacridine (ACMA); ABQ; Acid Fuchsin; Acridine Orange; Acridine Red; Acridine Yellow; Acriflavin; Acriflavin Feulgen SITSA; Aequorin (Photoprotein); AFPs - AutoFluorescent Protein - (Quantum Biotechnologies) see sgGFP, sgBFP; Alexa Fluor 350; Alexa Fluor 430; Alexa Fluor 488; Alexa Fluor 532; Alexa Fluor 546; Alexa Fluor 568; Alexa Fluor 594; Alexa Fluor 633; Alexa Fluor 647; Alexa Fluor 660; Alexa Fluor 680; Alizarin Complexon; Alizarin Red; Allophycocyanin (APC); AMC, AMCA-S; Aminomethylcoumarin (AMCA); AMCA-X; Aminoactinomycin D; Aminocoumarin; Anilin Blue; Anthrocyl stearate; APC-Cy7; APTRA-BTC; APTS; Astrazon Brilliant Red 4G; Astrazon Orange R; Astrazon Red 6B; Astrazon Yellow 7 GLL; Atabrine; ATTO- TAG CBQCA; ATTO-TAG FQ; Auramine; Aurophosphine G; Aurophosphine; BAO 9 (Bisaminophenyloxadiazole); BCECF (high pH); BCECF (low pH); Berberine Sulphate; Beta Lactamase; BFP blue shifted GFP (Y66H); Blue Fluorescent Protein; BFP / GFP FRET; Bimane; Bisbenzemide; Bisbenzimide (Hoechst); bis- BTC; Blancophor FFG; Blancophor SV; BOBO-1; BOBO-3; Bodipy492 / 515; Bodipy493 / 503; Bodipy500 / 510; Bodipy; 505 / 515; Bodipy 530 / 550; Bodipy 542 / 563; Bodipy 558 / 568; Bodipy 564 / 570; Bodipy 576 / 589; Bodipy 581 / 591; Bodipy 630 / 650-X; Bodipy 650 / 665-X; Bodipy 665 / 676; Bodipy Fl; Bodipy FL ATP; Bodipy Fl-Ceramide; Bodipy R6G SE; Bodipy TMR; Bodipy TMR-X conjugate; Bodipy TMR-X, SE; Bodipy TR; Bodipy TR ATP; Bodipy TR-X SE; BO-PRO-1; BO-PRO-3; Brilliant Sulphoflavin FF; BTC; BTC-5N; Calcein; Calcein Blue; Calcium Crimson - ; Calcium Green; Calcium Green-1 Ca2+Dye; Calcium Green-2 Ca2+; Calcium Green-5N Ca2+; Calcium Green-C18 Ca2+; Calcium Orange; Calcofluor White; Carboxy-X-rhodamine (5-ROX); Cascade Blue; Cascade Yellow; Catecholamine; CCF2 (GeneBlazer); CFDA; CFP (Cyan Fluorescent Protein); CFP / YFP FRET; Chlorophyll; Chromomycin A; Chromomycin A; CL-NERF; CMFDA; Coelenterazine; Coelenterazine cp; Coelenterazine f; Coelenterazine fcp; Coelenterazine h; Coelenterazine hcp; Coelenterazine ip; Coelenterazine n; Coelenterazine O; Coumarin Phalloidin; C-phycocyanine; CPM I Methylcoumarin; CTC; CTC Formazan; Cy2; Cy3.18; Cy3.5; Cy3; Cy5.1 8; Cy5.5; Cy5; Cy7; Cyan GFP; cyclic AMP Fluorosensor (FiCRhR); Attorney Docket No.11196-112WO1 Dabcyl; Dansyl; Dansyl Amine; Dansyl Cadaverine; Dansyl Chloride; Dansyl DHPE; Dansyl fluoride; DAPI; Dapoxyl; Dapoxyl 2; Dapoxyl 3’DCFDA; DCFH (Dichlorodihydrofluorescein Diacetate); DDAO; DHR (Dihydorhodamine 123); Di-4- ANEPPS; Di-8-ANEPPS (non-ratio); DiA (4-Di 16-ASP); Dichlorodihydrofluorescein Diacetate (DCFH); DiD- Lipophilic Tracer; DiD (DilC18(5)); DIDS; Dihydorhodamine 123 (DHR); Dil (DilC18(3)); I Dinitrophenol; DiO (DiOC18(3)); DiR; DiR (DilC18(7)); DM- NERF (high pH); DNP; Dopamine; DsRed; DTAF; DY-630-NHS; DY-635-NHS; EBFP; ECFP; EGFP; ELF 97; Eosin; Erythrosin; Erythrosin ITC; Ethidium Bromide; Ethidium homodimer-1 (EthD-1); Euchrysin; EukoLight; Europium (111) chloride; EYFP; Fast Blue; FDA; Feulgen (Pararosaniline); FIF (Formaldehyd Induced Fluorescence); FITC; Flazo Orange; Fluo-3; Fluo-4; Fluorescein (FITC); Fluorescein Diacetate; Fluoro-Emerald; Fluoro-Gold (Hydroxystilbamidine); Fluor-Ruby; FluorX; FM 1-43Ô; FM 4-46; Fura Red (high pH); Fura Red / Fluo-3; Fura-2; Fura-2 / BCECF; Genacryl Brilliant Red B; Genacryl Brilliant Yellow 10GF; Genacryl Pink 3G; Genacryl Yellow 5GF; GeneBlazer; (CCF2); GFP (S65T); GFP red shifted (rsGFP); GFP wild type’ non-UV excitation (wtGFP); GFP wild type, UV excitation (wtGFP); GFPuv; Gloxalic Acid; Granular blue; Haematoporphyrin; Hoechst 33258; Hoechst 33342; Hoechst 34580; HPTS; Hydroxycoumarin; Hydroxystilbamidine (FluoroGold); Hydroxytryptamine; Indo-1, high calcium; Indo-1 low calcium; Indodicarbocyanine (DiD); Indotricarbocyanine (DiR); Intrawhite Cf; JC-1; JO JO-1; JO-PRO-1; LaserPro; Laurodan; LDS 751 (DNA); LDS 751 (RNA); Leucophor PAF; Leucophor SF; Leucophor WS; Lissamine Rhodamine; Lissamine Rhodamine B; Calcein / Ethidium homodimer; LOLO-1; LO-PRO-1; ; Lucifer Yellow; Lyso Tracker Blue; Lyso Tracker Blue-White; Lyso Tracker Green; Lyso Tracker Red; Lyso Tracker Yellow; LysoSensor Blue; LysoSensor Green; LysoSensor Yellow / Blue; Mag Green; Magdala Red (Phloxin B); Mag-Fura Red; Mag-Fura-2; Mag-Fura-5; Mag-lndo-1; Magnesium Green; Magnesium Orange; Malachite Green; Marina Blue; I Maxilon Brilliant Flavin 10 GFF; Maxilon Brilliant Flavin 8 GFF; Merocyanin; Methoxycoumarin; Mitotracker Green FM; Mitotracker Orange; Mitotracker Red; Mitramycin; Monobromobimane; Monobromobimane (mBBr-GSH); Monochlorobimane; MPS (Methyl Green Pyronine Stilbene); NBD; NBD Amine; Nile Red; Nitrobenzoxedidole; Noradrenaline; Nuclear Fast Red; i Nuclear Yellow; Nylosan Brilliant lavin E8G; Oregon Green; Oregon Green 488; Oregon Green 500; Oregon Green 514; Pacific Blue; Pararosaniline (Feulgen); PBFI; PE-Cy5; PE-Cy7; PerCP; PerCP-Cy5.5; PE-TexasRed (Red 613); Phloxin B (Magdala Red); Phorwite AR; Phorwite BKL; Phorwite Rev; Attorney Docket No.11196-112WO1 Phorwite RPA; Phosphine 3R; PhotoResist; Phycoerythrin B [PE]; Phycoerythrin R [PE]; PKH26 (Sigma); PKH67; PMIA; Pontochrome Blue Black; POPO-1; POPO-3; PO-PRO-1; PO- I PRO-3; Primuline; Procion Yellow; Propidium lodid (Pl); PyMPO; Pyrene; Pyronine; Pyronine B; Pyrozal Brilliant Flavin 7GF; QSY 7; Quinacrine Mustard; Resorufin; RH 414; Rhod-2; Rhodamine; Rhodamine 110; Rhodamine 123; Rhodamine 5 GLD; Rhodamine 6G; Rhodamine B; Rhodamine B 200; Rhodamine B extra; Rhodamine BB; Rhodamine BG; Rhodamine Green; Rhodamine Phallicidine; Rhodamine: Phalloidine; Rhodamine Red; Rhodamine WT; Rose Bengal; R-phycocyanine; R-phycoerythrin (PE); rsGFP; S65A; S65C; S65L; S65T; Sapphire GFP; SBFI; Serotonin; Sevron Brilliant Red 2B; Sevron Brilliant Red 4G; Sevron I Brilliant Red B; Sevron Orange; Sevron Yellow L; sgBFPÔ (super glow BFP); sgGFP (super glow GFP); SITS (Primuline; Stilbene Isothiosulphonic Acid); SNAFL calcein; SNAFL-1; SNAFL-2; SNARF calcein; SNARF1; Sodium Green; SpectrumAqua; SpectrumGreen; SpectrumOrange; Spectrum Red; SPQ (6-methoxy- N-(3 sulfopropyl) quinolinium); Stilbene; Sulphorhodamine B and C; Sulphorhodamine Extra; SYTO 11; SYTO 12; SYTO 13; SYTO 14; SYTO 15; SYTO 16; SYTO 17; SYTO 18; SYTO 20; SYTO 21; SYTO 22; SYTO 23; SYTO 24; SYTO 25; SYTO 40; SYTO 41; SYTO 42; SYTO 43; SYTO 44; SYTO 45; SYTO 59; SYTO 60; SYTO 61; SYTO 62; SYTO 63; SYTO 64; SYTO 80; SYTO 81; SYTO 82; SYTO 83; SYTO 84; SYTO 85; SYTOX Blue; SYTOX Green; SYTOX Orange; Tetracycline; Tetramethylrhodamine (TRITC); Texas RedÔ; Texas Red-XÔ conjugate; Thiadicarbocyanine (DiSC3); Thiazine Red R; Thiazole Orange; Thioflavin 5; Thioflavin S; Thioflavin TON; Thiolyte; Thiozole Orange; Tinopol CBS (Calcofluor White); TIER; TO-PRO-1; TO-PRO-3; TO-PRO-5; TOTO-1; TOTO-3; TriColor (PE-Cy5); TRITC TetramethylRodaminelsoThioCyanate; True Blue; Tru Red; Ultralite; Uranine B; Uvitex SFC; wt GFP; WW 781; X-Rhodamine; XRITC; Xylene Orange; Y66F; Y66H; Y66W; Yellow GFP; YFP; YO-PRO-1; YO- PRO 3; YOYO-1;YOYO-3; Sybr Green; Thiazole orange (interchelating dyes); semiconductor nanoparticles such as quantum dots; or caged fluorophore (which can be activated with light or other electromagnetic energy source), or a combination thereof. In some aspects, the optional one or more additional monomers may comprise riboflavin. In some aspects, the polymer or oligomer is crosslinked. In some aspects, the polymer or oligomer can be thermally crosslinked, radically crosslinked, chemically crosslinked, ionically crosslinked, or combinations thereof. Attorney Docket No.11196-112WO1 In some aspects, the polymer or oligomer can be crosslinked by one or more crosslinkers. Any crosslinker not inconsistent with the objectives of the present disclosure may be used. In some cases, for example, a crosslinker comprises one or more olefins or olefinic moieties that can be used to crosslink polymers containing ethylenically unsaturated moieties. In some embodiments, a crosslinker comprises an acrylate or polyacrylate, including a diacrylate. In other embodiments, a crosslinker comprises one or more of 1,3- butanediol diacrylate, 1,6-hexanediol diacrylate, glycerol 1,3-diglyerolate diacrylate, d(ethylene glycol) diacrylate, poly(ethylene glycol) diacrylate, poly(propylene glycol) diacrylate, and propylene glycol glycerolate diacrylate. In some aspects, the one or more crosslinkers may comprise one or more diisocyanates. In some aspects, the isocyanate comprises an alkane diisocyanate having four to twenty carbon atoms. An isocyanate described herein may also include a monocarboxylic acid moiety. Further examples of various isocyanates which can be used are described in U.S. Patent Application Publication No. 2020 / 0140607 and International Patent Application Publication No. WO2018 / 227151, the contents of which are incorporated herein in their entirety. In some embodiments, a crosslinker comprises an ionic crosslinker. For instance, in some embodiments, a polymer or oligomer is crosslinked with a multivalent metal ion, such as a transition metal ion. In some embodiments, a multivalent metal ion used as a crosslinker of the polymer or oligomer comprises one or more of Fe, Ni, Cu, Zn, or Al, including in the +2 or +3 state. A crosslinker described herein can be present in a composition in any amount not inconsistent with the objective of the present disclosure. For example, in some aspects, a crosslinker is present in a composition in an amount between about 5 weight percent and about 50 weight percent, between about 5 weight percent and about 40 weight percent, between about 5 weight percent and about 30 weight percent, between about 10 weight percent and about 40 weight percent, between about 10 weight percent and about 30 weight percent, or between about 20 weight percent and about 40 weight percent, based on the total weight of the composition. Thus, in some aspects, the composition described herein comprises a polymer or oligomer described herein that is crosslinked to from a polymer network. In some embodiments, the polymer network comprises a hydrogel. A hydrogel, in some cases, comprises an aqueous continuous phase and polymeric disperse or discontinuous phase. Attorney Docket No.11196-112WO1 Further in some aspects, the crosslinked polymer network described herein is not water soluble. Such a polymer network can have a high cross-linking density. “Cross-linking density”, for reference purposes herein, can refer to the number of cross-links between polymer backbones or the molecular weight between cross-linking sites. Cross-links may include, for example, ester bonds formed by the esterification or reaction of one or more pendant carboxyl or carboxylic acid groups with one or more pendant hydroxyl groups of adjacent polymer backbones. In some aspects, a polymer network described herein has a cross-linking density of at least about 500, at least about 1000, at least about 5000, at least about 7000, at least about 10,000, at least about 20,000, or at least about 30,000 mol / m3. In some embodiments, the cross-linking density is between about 600 and about 70,000, or between about 10,000 and about 70,000 mol / m3. In some aspects, the ocular implant may further comprise one or more therapeutic agents. Suitable therapeutic agents include any which may find use in treating an ophthalmic disorder or other related disorder. Representative types of suitable therapeutic agents include, but are not limited to, alpha agonists, aminoglycosides, anesthetics, ANG-2 inhibitors, antibiotics, anticholinergic agents, antihistamines, antivirals, beta blockers, carbonic anhydrase inhibitors, ciliary neurotrophic factor, complement inhibitors, corticosteroids, cycloplegics, decongestants, LFA-1 agonists, lubricants, macrolides, macular degeneration agents, mast cell stabilizers, miotics, mydriatics, non-steroidal anti- inflammatory drugs, prostaglandin agonists, quinolones, RASP inhibitors, VEGF inhibitors, or vitreolytics. Exemplary therapeutic agents which are suitable include, but are not limited to, bicipar pegol, acetazolamide, acetylcholine, aclaftadine, acyclovir, aflibercept, apraclonidine, atropine, acacincaptad pegol, azelastine, azithromycin, bacitracin, benoxinate, bepotastine, besifloxacin, betaxolol, bevacizumab, bitamoprost, brinzolamide, brolucizumab, bromfenac, bromonidine, carbachol, carteolol, cenegermin, cetirizine, chloroprocaine, ciprofloxacin, clobetasol, cromolyn sodium, cyclopentolate, cyclosporine, cysteamine, dexamethasone, diclofenac, difluprednate, dorzolamide, echothiophate iodide, emedastine, epinastine, erythromycin, faricimab, fluocinolone, fluorometholone, flurbiprofen, ganciclovir, garamycin, gatifloxacin, gentamicin, hydroxyamphetamine, ketorolac, ketotifen, latanoprost, latanoprostene bunod, levobunolol, levofloxacin, lidocaine, lifitegrast, lodoxamide, loteprednol, lopidine, metipranolol, methazolamide, mitomycin, Attorney Docket No.11196-112WO1 moxifloxacin, naphazoline, natamycin, nedocromil, neomycin, nepafenac, netarsudil, ocriplasmin, ofloxacin, olopatadine, oxymetazoline, perfluorohexyloctane, pegaptanib, pegcetacoplan, pheniramine, phentolamide, phenylephrine, pilocarpine, polymyxin B, prednisolone, proparacaine, ranibizumab, reproxalap, revakinagene taroretcel, rimexolone, sulfacetamide, tafluprost, tetrahydrozoline, timolol, tobramycin, travoprost, triamcinolone, trifluridine, trimethoprim, tropicamide, or combinations thereof. In some aspects, the one or more therapeutic agents comprise an anti-inflammatory agent, an antioxidant, an antimicrobial agent, or combinations thereof. In some aspects, the one or more therapeutic agents are selected from sodium bromfenac, axitinib, travoprost, dexamethasone, prednisolone, cyclosporin, vancomycin, or combinations thereof. In some particular aspects, the one or more therapeutic agents comprises sodium bromfenac. In some aspects, the one or more therapeutic agents are incorporated into the polymer or oligomer. In some aspects, the one or more therapeutic agents are incorporated into the polymer or oligomer via being covalently bound to the polymer or oligomer. In some aspects, the one or more therapeutic agents are incorporated into a backbone of the polymer or oligomer or are a pendant group of the polymer or oligomer. In such aspects, the one or more therapeutic agents may be incorporated during synthesis of the polymer or oligomer, for example via the one or more therapeutics being a monomer used in the preparation of the polymer or oligomer. In other aspects, the one or more therapeutic agents may be incorporated into the polymer or oligomer without being covalently bound to the polymer or oligomer. For example, the one or more therapeutic agents m beay incorporated via physical mixing with the polymer or oligomer. In some aspects, the one or more therapeutic agents are encapsulated within particles, for example nanoparticles or microspheres. In some aspects, the particles are dispersed within the polymer or oligomer. In some aspects, the particles comprise a polymer. In some aspects, the particles comprise a citrate-containing polymer. Further examples of suitable polymers for the particles include, but are not limited to, poly(lactic acid), poly(caprolactone), poly(lactic-co-glycolic acid), gelatin, hyaluronic acid, collagen, or combinations thereof. In some aspects, the one or more therapeutic agents are released from the ocular implants over a time period ranging from about one day to about six months, including the Attorney Docket No.11196-112WO1 exemplary values of about one day, about five days, about ten days, about 15 days, about 20 days, about 25 days, about one month, about two months, about three months, about four months, about five months, about six months, or any subrange formed from the above exemplary values. In another aspect, a polymer or oligomer is provided formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; one or more therapeutic agents; and optionally one or more additional monomers. In some aspects, the one or more therapeutic agents comprise at least two polymerizable functional groups. In some aspects, the one or more therapeutic agents are covalently bound to the polymer or oligomer. In some aspects, the one or more therapeutic agents are incorporated into a backbone of the polymer or oligomer or are a pendant group of the polymer or oligomer. In some aspects, the ocular implant has porosity. Porosity may be instilled in the implant via any suitable technique identified in the art. In some aspects, the porosity is formed via leaching of a porogen (for example, sodium chloride). In other aspects, the porosity is formed via gas foaming. In further aspects, the porosity is formed via thermally induced phase separation. In some aspects, the polymer or oligomer has a tensile strength ranging from about 0.5 MPa to about 150 MPa in a dry state, including exemplary values of about 0.5 MPa, about 1 MPa, about 5 MPa, about 10 MPa, about 20 MPa, about 30 MPa, about 40 MPa, about 50 MPa, about 60 MPa, about 70 MPa, about 80 MPa, about 90 MPa, about 100 MPa, about 110 MPa, about 120 MPa, about 130 MPa, about 140 MPa, about 150 MPa, or any subrange formed from the above exemplary values. In some aspects, the polymer or oligomer has a tensile strain ranging from about 1% to about 200% in a dry state, including exemplary values of about 1%, about 5%, about 10%, about 20%, about 40%, about 50%, about 60%, about 80%, about 100%, about 120%, about 140%, about 150%, about 160%, about 180%, about 200%, or any subrange formed from the above exemplary values. Attorney Docket No.11196-112WO1 In some aspects, solution uptake by the polymer or oligomer results in volume swelling from about 1% to about 500%, including exemplary values of about 1%, about 10%, about 50%, about 100%, about 150%, about 200%, about 250%, about 300%, about 350%, about 400%, about 450%, about 500%, or any subrange formed from the above exemplary values. In some aspects, swelling of the polymer or oligomer may anchor the implant and / or polymer or oligomer to tissue at a site of administration. In some aspects, polymer or oligomer s as described herein may transition from a rigid dry state to an elastic wet state. In some aspects, the polymer or oligomer maintains a wet mechanics of up to about 10 MPA for a period up to about four weeks, including exemplary values of up to about 0.5 MPa, about 1 MPa, about 2 MPa, about 3 MPa, about 4 MPa, about 5 MPa, about 6 MPa, about 7 MPa, about 8 MPa, about 9 MPa, about 10 MPa, or any subrange formed from the above exemplary values. In some aspects, the polymer or oligomer maintains a wet modulus of up to about 10 MPa for a period of up to about four weeks, including exemplary values of up to about 0.5 MPa, about 1 MPa, about 2 MPa, about 3 MPa, about 4 MPa, about 5 MPa, about 6 MPa, about 7 MPa, about 8 MPa, about 9 MPa, about 10 MPa, or any subrange formed from the above exemplary values. In some aspects, the polymer or oligomer maintains a wet strain of up to about 300% for a period of up to four weeks including exemplary values of up to about 50%, about 100%, about 150%, about 200%, about 250%, about 300%, or any subrange formed from the above exemplary values. In some aspects, the polymer or oligomer is biodegradable. In some aspects, the polymer or oligomer degrades over a time period from about one week to about six months, including exemplary values of about one week, about two weeks, about three weeks, about one month, about two months, about three months, about four months, about five months, about six months, or any subrange formed from the above exemplary values. In some aspects, polymers or oligomers as described herein may be fluorescent. In some aspects, the polymers or oligomers are intrinsically fluorescent. Polymers as described herein may fluoresce at a wavelength from about 250 nm to about 700 nm. The fluorescence of the polymer or oligomer may prove useful for imaging of the implant or tracking of the degradation of the implant. In some aspects, the polymers or oligomers may incorporate Attorney Docket No.11196-112WO1 additional monomers resulting in fluorescence. Examples of such monomers include those containing primary amines. In some aspects, such monomers comprise amino acids, for example cysteine or serine. In some aspects, polymers or oligomers as described herein may promote cell viability and proliferation. In some aspects, polymers or oligomers as described herein may inhibit gram positive bacteria, gram negative bacteria, fungi, or the like. In some aspects, polymers or oligomers as described herein may inhibit inflammation and / or pro- inflammatory polarization of macrophages. In some aspects, polymers or oligomers as described herein may have absorbance properties between about 250 nm and about 2000 nm. In some aspects, the absorbance properties may be the result of incorporation of ascorbic acid into the polymer or oligomer. In some aspects, polymers or oligomers as described herein may have absorbance based photoacoustic and ultrasound imaging properties. Such absorbance properties may be used, for example, for imaging within tissues, tracking implant degradation, for photothermal applications, to stimulate cells or tissues, or to inhibit bacterial, fungal, or cellular growth. In some aspects, polymers or oligomers as described herein may have UV blocking properties. In other aspects, polymers or oligomers as described herein may have light transmission between about 400 nm and about 2000 nm. Light transmission may be used to delivery light through the polymer or oligomer. In further aspects, polymers or oligomers as described herein may have concurrent fluorescent and photoacoustic imaging properties. In some aspects, polymers or oligomers as described herein are capable of inhibiting oxidation due to the presence of certain monomers in their formation. In some aspects, such monomers may include citrate or xylitol. In other aspects, such monomers may include, but are not limited to, ascorbic acid, itaconic acid, tannic acid, gallic acid, or 4-hydroxybenzyl alcohol. polymers or oligomers as described herein (such as those used in the ocular implants described herein) may be synthesized by first reacting the associated monomers (e.g., citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; and optionally one or more additional monomers) to form prepolymers. Such prepolymers may typically have a weight ranging from about 1,000 Daltons to about 2,500 Daltons. Such prepolymers may be synthesized at temperatures ranging from about 100 degrees Celsius to about 160 degrees Celsius. The prepolymers may then be further thermally crosslinked. Such thermal Attorney Docket No.11196-112WO1 crosslinking may occur at temperatures between about 80 degrees Celsius to about 120 degrees Celsius. Thermal crosslinking may be performed over a period from about one day to about seven days. The ocular implants described herein may have any structure which would be deemed suitable for the intended area of administration. For example, implants which may be designed for intracanalicular administration may comprise a tapered structure which may have advantages for that site of administration. In some aspects, the implants and / or polymers or oligomers described herein may be injectable, for example in the form of a hydrogel. In some aspects, the implants described herein release degradation products after administration which may have various therapeutic functions, either from the degraded components of the associated polymer or oligomer itself or via release of therapeutic agents incorporated therein. Methods of Treatment The present disclosure further provides methods of treating an ophthalmic disease or disorder by administering an ocular implant or polymer or oligomer as described herein. The subject can be a patient; and the patient can have been diagnosed with an ophthalmic disorder. In some aspects, the method can further comprise diagnosing a subject with an ophthalmic disorder. The ophthalmic disorder can be acute macular neuroretinopathy; Behcet's disease; neovascularization, including choroidal neovascularization; diabetic uveitis; histoplasmosis; infections, such as fungal or viral-caused infections; macular degeneration, such as acute macular degeneration (AMD), including wet AMD, non-exudative AMD and exudative AMD; edema, such as macular edema, cystoid macular edema and diabetic macular edema; multifocal choroiditis; ocular trauma which affects a posterior ocular site or location; ocular tumors; retinal disorders, such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic retinopathy), proliferative vitreoretinopathy (PVR), retinal arterial occlusive disease, retinal detachment, uveitic retinal disease; sympathetic opthalmia; Vogt Koyanagi-Harada (VKH) syndrome; uveal diffusion; a posterior ocular condition caused by or influenced by an ocular laser treatment; posterior ocular conditions caused by or influenced by a photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membrane disorders, branch retinal vein occlusion, anterior ischemic optic neuropathy, non- Attorney Docket No.11196-112WO1 retinopathy diabetic retinal dysfunction, retinitis pigmentosa, a cancer, and glaucoma. In certain instances, the ophthalmic disorder is wet age-related macular degeneration (wet AMD), a cancer, neovascularization, macular edema, or edema. In a further particular aspect, the ophthalmic disorder is wet age-related macular degeneration (wet AMD). “Ocular region” or “ocular site” means any area of the ocular globe (eyeball), including the anterior and posterior segment of the eye, and which generally includes, but is not limited to, any functional (e.g., for vision) or structural tissues found in the eyeball, or tissues or cellular layers that partly or completely line the interior or exterior of the eyeball. Specific examples of areas of the eyeball in an ocular region include, but are not limited to, the anterior chamber, the posterior chamber, the vitreous cavity, the choroid, the suprachoroidal space, the conjunctiva, the subconjunctival space, the episcleral space, the intracorneal space, the subretinal space, sub-Tenon's space, the epicorneal space, the sclera, the pars plana, surgically-induced avascular regions, the macula, and the retina. “Ophthalmic disorder” can mean a disease, ailment or condition which affects or involves the eye or one of the parts or regions of the eye. Broadly speaking, the eye includes the eyeball, including the cornea, and other tissues and fluids which constitute the eyeball, the periocular muscles (such as the oblique and rectus muscles) and the portion of the optic nerve which is within or adjacent to the eyeball. “Glaucoma” means primary, secondary and / or congenital glaucoma. Primary glaucoma can include open angle and closed angle glaucoma. Secondary glaucoma can occur as a complication of a variety of other conditions, such as injury, inflammation, pigment dispersion, vascular disease and diabetes. The increased pressure of glaucoma causes blindness because it damages the optic nerve where it enters the eye. “Inflammation-mediated” in relation to an ocular condition means any condition of the eye which can benefit from treatment with an anti-inflammatory agent, and is meant to include, but is not limited to, uveitis, macular edema, acute macular degeneration, retinal detachment, ocular tumors, fungal or viral infections, multifocal choroiditis, diabetic retinopathy, uveitis, proliferative vitreoretinopathy (PVR), sympathetic ophthalmia, Vogt- Koyanagi-Harada (VKH) syndrome, histoplasmosis, and uveal diffusion. “Injury” or “damage” in relation to an ocular condition are interchangeable and refer to the cellular and morphological manifestations and symptoms resulting from an inflammatory-mediated condition, such as, for example, inflammation, as well as tissue Attorney Docket No.11196-112WO1 injuries caused by means other than inflammation, such as chemical injury, including chemical burns, as well as injuries caused by infections, including but not limited to, bacterial, viral, or fungal infections. “Intraocular” means within or under an ocular tissue. An intraocular administration of an implant includes administration of the implant system to a sub-tenon, subconjunctival, suprachoroidal, subretinal, intravitreal, anterior chamber, and the like location. An intraocular administration of an implant excludes administration of the drug delivery system to a topical, systemic, intramuscular, subcutaneous, intraperitoneal, and the like location. “Macular degeneration” refers to any of a number of disorders and conditions in which the macula degenerates or loses functional activity. The degeneration or loss of functional activity can arise as a result of, for example, cell death, decreased cell proliferation, loss of normal biological function, or a combination of the foregoing. Macular degeneration can lead to and / or manifest as alterations in the structural integrity of the cells and / or extracellular matrix of the macula, alteration in normal cellular and / or extracellular matrix architecture, and / or the loss of function of macular cells. The cells can be any cell type normally present in or near the macula including RPE cells, photoreceptors, and capillary endothelial cells. Age-related macular degeneration, or ARMD, is the major macular degeneration related condition, but a number of others are known including, but not limited to, Best macular dystrophy, Stargardt macular dystrophy, Sorsby fundus dystrophy, Mallatia Leventinese, Doyne honeycomb retinal dystrophy, and RPE pattern dystrophies. Age-related macular degeneration (AMD) is described as either “dry” or “wet.” The wet, exudative, neovascular form of AMD affects about 10-20% of those with AMD and is characterized by abnormal blood vessels growing under or through the retinal pigment epithelium (RPE), resulting in hemorrhage, exudation, scarring, or serous retinal detachment. Eighty to ninety percent of AMD patients have the dry form characterized by atrophy of the retinal pigment epithelium and loss of macular photoreceptors. Drusen may or may not be present in the macula. There may also be geographic atrophy of retinal pigment epithelium in the macula accounting for vision loss. At present there is no cure for any form of AMD, although some success in attenuation of wet AMD has been obtained with photodynamic and especially anti-VEGF therapy. “Drusen” is debris-like material that accumulates with age below the RPE. Drusen is observed using a funduscopic eye examination. Normal eyes may have maculas free of drusen, yet drusen may be abundant in the retinal periphery. The presence of soft drusen in Attorney Docket No.11196-112WO1 the macula, in the absence of any loss of macular vision, is considered an early stage of AMD. Drusen contains a variety of lipids, polysaccharides, and glycosaminoglycans along with several proteins, modified proteins or protein adducts. There is no generally accepted therapeutic method that addresses drusen formation and thereby manages the progressive nature of AMD. “Ocular neovascularization” (ONV) is used herein to refer to choroidal neovascularization or retinal neovascularization, or both. “Retinal neovascularization” (RNV) refers to the abnormal development, proliferation, and / or growth of retinal blood vessels, e.g., on the retinal surface. “Subretinal neovascularization” (SRNVM) refers to the abnormal development, proliferation, and / or growth of blood vessels beneath the surface of the retina. “Cornea” refers to the transparent structure forming the anterior part of the fibrous tunic of the eye. It consists of five layers, specifically: 1) anterior corneal epithelium, continuous with the conjunctiva; 2) anterior limiting layer (Bowman's layer); 3) substantia propria, or stromal layer; 4) posterior limiting layer (Descemet's membrane); and 5) endothelium of the anterior chamber or keratoderma. “Retina” refers to the innermost layer of the ocular globe surrounding the vitreous body and continuous posteriorly with the optic nerve. The retina is composed of layers including the: 1) internal limiting membrane; 2) nerve fiber layer; 3) layer of ganglion cells; 4) inner plexiform layer; 5) inner nuclear layer; 6) outer plexiform layer; 7) outer nuclear layer; 8) external limiting membrane; and 9) a layer of rods and cones. “Retinal degeneration” refers to any hereditary or acquired degeneration of the retina and / or retinal pigment epithelium. Non-limiting examples include retinitis pigmentosa, Best's Disease, RPE pattern dystrophies, and age-related macular degeneration. In various aspects, a method of treating an ophthalmic disorder may comprise treatment of various ocular diseases or conditions of the retina, including the following: maculopathies / retinal degeneration: macular degeneration, including age-related macular degeneration (ARMD), such as non-exudative age-related macular degeneration and exudative age-related macular degeneration; choroidal neovascularization; retinopathy, including diabetic retinopathy, acute and chronic macular neuroretinopathy, central serous chorioretinopathy; and macular edema, including cystoid macular edema, and diabetic macular edema. Uveitis / retinitis / choroiditis: acute multifocal placoid pigment Attorney Docket No.11196-112WO1 epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, infectious (syphilis, Lyme Disease, tuberculosis, toxoplasmosis), uveitis, including intermediate uveitis (pars planitis) and anterior uveitis, multifocal choroiditis, multiple evanescent white dot syndrome (MEWDS), ocular sarcoidosis, posterior scleritis, serpignous choroiditis, subretinal fibrosis, uveitis syndrome, and Vogt-Koyanagi-Harada syndrome. Vascular diseases / exudative diseases: retinal arterial occlusive disease, central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coats disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, Eales disease, Traumatic / surgical diseases: sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, laser, PDT, photocoagulation, hypoperfusion during surgery, radiation retinopathy, bone marrow transplant retinopathy. Proliferative disorders: proliferative vitreal retinopathy and epiretinal membranes, proliferative diabetic retinopathy. Infectious disorders: ocular histoplasmosis, ocular toxocariasis, ocular histoplasmosis syndrome (OHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associated with HIV infection, uveitic disease associated with HIV Infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis. Genetic disorders: retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigment epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, pseudoxanthoma elasticum. Retinal tears / holes: retinal detachment, macular hole, giant retinal tear. Tumors: retinal disease associated with tumors, congenital hypertrophy of the RPE, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigment epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, intraocular lymphoid tumors. Miscellaneous: punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, acute retinal pigment epithelitis and the like. Attorney Docket No.11196-112WO1 An anterior ocular condition is a disease, ailment or condition which affects, or which involves an anterior (i.e., front of the eye) ocular region or site, such as a periocular muscle, an eyelid or an eyeball tissue or fluid which is located anterior to the posterior wall of the lens capsule or ciliary muscles. Thus, an anterior ocular condition primarily affects or involves the conjunctiva, the cornea, the anterior chamber, the iris, the posterior chamber (behind the iris but in front of the posterior wall of the lens capsule), the lens or the lens capsule and blood vessels and nerve which vascularize or innervate an anterior ocular region or site. Thus, an anterior ocular condition can include a disease, ailment or condition, such as for example, aphakia; pseudophakia; astigmatism; blepharospasm; cataract; conjunctival diseases; conjunctivitis, including, but not limited to, atopic keratoconjunctivitis; corneal injuries, including, but not limited to, injury to the corneal stromal areas; corneal diseases; corneal ulcer; dry eye syndromes; eyelid diseases; lacrimal apparatus diseases; lacrimal duct obstruction; myopia; presbyopia; pupil disorders; refractive disorders and strabismus. Glaucoma can also be considered to be an anterior ocular condition because a clinical goal of glaucoma treatment can be to reduce a hypertension of aqueous fluid in the anterior chamber of the eye (i.e. reduce intraocular pressure). Other diseases or disorders of the eye which may be treated in accordance with the present disclosure include, but are not limited to, ocular cicatricial pemphigoid (OCP), Stevens Johnson syndrome and cataracts. A posterior ocular condition is a disease, ailment or condition which primarily affects or involves a posterior ocular region or site such as choroid or sclera (in a position posterior to a plane through the posterior wall of the lens capsule), vitreous, vitreous chamber, retina, optic nerve (i.e., the optic disc), and blood vessels and nerves which vascularize or innervate a posterior ocular region or site. Thus, a posterior ocular condition can include a disease, ailment or condition, such as for example, acute macular neuroretinopathy; Behcet's disease; choroidal neovascularization; diabetic retinopathy; uveitis; ocular histoplasmosis; infections, such as fungal or viral-caused infections; macular degeneration, such as acute macular degeneration, non-exudative age-related macular degeneration and exudative age-related macular degeneration; edema, such as macular edema, cystoid macular edema and diabetic macular edema; multifocal choroiditis; ocular trauma which affects a posterior ocular site or location; ocular tumors; retinal disorders, such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic Attorney Docket No.11196-112WO1 retinopathy), proliferative vitreoretinopathy (PVR), retinal arterial or venous occlusive disease, retinal detachment, uveitic retinal disease; sympathetic ophthalmia; Vogt-Koyanagi- Harada (VKH) syndrome; uveal diffusion; a posterior ocular condition caused by or influenced by an ocular laser treatment; posterior ocular conditions caused by or influenced by a photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membrane disorders, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, retinitis pigmentosa, and glaucoma. Glaucoma can be considered a posterior ocular condition because the therapeutic goal is to prevent the loss of or reduce the occurrence of loss of vision due to damage to or loss of retinal ganglion cells or retinal nerve fibers (i.e., neuroprotection). In some aspects, the ophthalmic disorder is ocular inflammation resulting from, e.g., iritis, conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, masquerade syndromes including ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion and blood-aqueous barrier disruption. In yet another aspect, the ophthalmological disorder is post-operative ocular inflammation resulting from, for example, photorefractive keratectomy, cataract removal surgery, intraocular lens implantation, vitrectomy, corneal transplantation, forms of lamellar keratectomy (DSEK, etc.), and radial keratotomy. The implants and / or polymers or oligomers described herein may be administered in such amounts, time, and route deemed necessary in order to achieve the desired result. The exact amount will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the medical disorder, the particular implants or polymers or oligomers used, its mode of administration, its mode of activity, and the like. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the implant or polymer or oligomer employed; the specific composition of the implant or polymer or oligomer employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific implant or polymer or oligomer employed; the duration of the treatment; drugs used in combination or coincidental with the specific implant or polymer or oligomer employed; and like factors well known in the medical arts. Attorney Docket No.11196-112WO1 The exact amount of implant or polymer or oligomer required to achieve a therapeutically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult. Useful dosages can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art. The dosage ranges for the administration of the implants or polymers or oligomers described herein are those large enough to produce the desired effect in which the symptoms or disorder are affected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary and can be administered in one or more dose administrations. Additional Aspects In view of the described devices, compositions, and methods, hereinbelow are described certain more particular aspects of the disclosure. These particularly recited aspects should not, however, be interpreted to have any limiting effect on any different claims containing different or more general teachings described herein, or that the “particular” aspects are somehow limited in some way other than the inherent meanings of the language and formulae literally used therein. Aspect 1. An ocular implant comprising a polymer or oligomer formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; and optionally one or more additional monomers. Attorney Docket No.11196-112WO1 Aspect 2. The ocular implant of aspect 1, wherein the ocular implant is suitable for placement within or proximal to the eye. Aspect 3. The ocular implant of aspect 1 or aspect 2, wherein the ocular implant is suitable for placement within an intracanalicular duct. Aspect 4. The ocular implant of aspect 1 or aspect 2, wherein the ocular implant is suitable for placement within a scleral membrane. Aspect 5. The ocular implant of aspect 1 or aspect 2, wherein the ocular implant is suitable for placement into a subconjunctival position and / or a parabular position. Aspect 6. The ocular implant of aspect 1 or aspect 2, wherein the ocular implant is suitable for placement into an intravitreal environment. Aspect 7. The ocular implant of any one of aspects 1-6, wherein the molar ratio of citric acid, or a salt or ester thereof, to 1,8-octanediol and xylitol is from about 3:1 to about 1:3. Aspect 8. The ocular implant of any one of aspects 1-7, wherein the molar ratio of 1,8- octanediol to xylitol is from about 3:1 to about 1:3. Aspect 9. The ocular implant of any one of aspects 1-8, wherein the one or more additional monomers comprise ascorbic acid, itaconic acid, tannic acid, gallic acid, 4- hydroxybenzyl alcohol, salts thereof, derivatives thereof, or combinations thereof. Aspect 10. The ocular implant of any one of aspects 1-9, wherein the one or more additional monomers comprise ascorbic acid or a salt or derivative thereof. Aspect 11. The ocular implant of any one of aspects 1-10, wherein the one or more additional monomers comprise itaconic acid or a salt or derivative thereof. Aspect 12. The ocular implant of any one of aspects 1-11, wherein the one or more additional monomers comprise a primary amine. Aspect 13. The ocular implant of aspect 12, wherein the primary amine comprises an amino acid or a salt or derivative thereof. Aspect 14. The ocular implant of aspect 13, wherein the amino acid comprises serine or cysteine, or a salt or derivative thereof. Aspect 15. The ocular implant of any one of aspects 1-14, wherein the one or more additional monomers comprise a fluorophore. Attorney Docket No.11196-112WO1 Aspect 16. The ocular implant of aspect 15, wherein the fluorophore comprises riboflavin. Aspect 17. The ocular implant of any one of aspects 1-16, wherein the polymer or oligomer is crosslinked. Aspect 18. The ocular implant of aspect 17, wherein the polymer or oligomer is thermally crosslinked. Aspect 19. The ocular implant of aspect 17, wherein the polymer or oligomer is radically crosslinked. Aspect 20. The ocular implant of aspect 17, wherein the polymer or oligomer is crosslinked by one or more crosslinkers. Aspect 21. The ocular implant of aspect 19, wherein the one or more crosslinkers comprise one or more diisocyanates. Aspect 22. The ocular implant of any one of aspects 1-21, further comprising one or more therapeutic agents. Aspect 23. The ocular implant of aspect 22, wherein the one or more therapeutic agents comprise an anti-inflammatory agent, an antioxidant, or an antimicrobial agent. Aspect 24. The ocular implant of aspect 22, wherein the one or more therapeutic agents are selected from sodium bromfenac, axitinib, travoprost, dexamethasone, prednisolone, cyclosporin, vancomycin, or combinations thereof. Aspect 25. The ocular implant of aspect 22, wherein the one or more therapeutic agents comprises sodium bromfenac. Aspect 26. The ocular implant of any one of aspects 22-25, wherein the one or more therapeutic agents are incorporated into the polymer or oligomer. Aspect 27. The ocular implant of aspect 26, wherein the one or more therapeutic agents are covalently bound to the polymer or oligomer. Aspect 28. The ocular implant of aspect 26, wherein the one or more therapeutic agents are incorporated into a backbone of the polymer or oligomer or are a pendant group of the polymer or oligomer. Aspect 29. The ocular implant of aspect 26, wherein the one or more therapeutic agents are incorporated during synthesis of the polymer or oligomer. Attorney Docket No.11196-112WO1 Aspect 30. The ocular implant of aspect 26, wherein the one or more therapeutic agents are incorporated via physical mixing with the polymer or oligomer. Aspect 31. The ocular implant of aspect 26, wherein the one or more therapeutic agents are encapsulated within particles. Aspect 32. The ocular implant of aspect 31, wherein the particles are dispersed within the polymer or oligomer. Aspect 33. The ocular implant of aspect 31 or aspect 32, wherein the particles comprise nanoparticles or microspheres. Aspect 34. The ocular implant of any one of aspects 31-33, wherein the particles comprise a citrate-containing polymer. Aspect 35. The ocular implant of any one of aspects 31-34, wherein the particles comprise a polymer selected from poly(lactic acid), poly(caprolactone), poly(lactic-co- glycolic acid), gelatin, hyaluronic acid, collagen, or combinations thereof. Aspect 36. The ocular implant of any one of aspects 22-34, wherein the one or more therapeutic agents are released from the ocular implants over a time period ranging from one day to six months. Aspect 37. The ocular implant of any one of aspects 1-36, wherein the ocular implant has porosity. Aspect 38. The ocular implant of aspect 37, wherein the porosity is formed via leaching of a porogen. Aspect 39. The ocular implant of aspect 37, wherein the porosity is formed via gas foaming. Aspect 40. The ocular implant of aspect 37, wherein the porosity is formed via thermally induced phase separation. Aspect 41. The ocular implant of any one of aspects 1-40, wherein the polymer or oligomer has a tensile strength ranging from about 0.5 MPa to about 150 MPa in a dry state. Aspect 42. The ocular implant of any one of aspects 1-41, wherein the polymer or oligomer has a tensile strain ranging from about 1% to about 200% in a dry state. Aspect 43. The ocular implant of any one of aspects 1-42, wherein solution uptake by the polymer or oligomer results in volume swelling from about 1% to about 500%. Attorney Docket No.11196-112WO1 Aspect 44. The ocular implant of any one of aspects 1-44, wherein the polymer or oligomer maintains a wet mechanics of up to about 10 MPA for a period up to about four weeks. Aspect 45. The ocular implant of any one of aspects 1-44, wherein the polymer or oligomer maintains a wet modulus of up to about 10 MPa for a period of up to about four weeks. Aspect 46. The ocular implant of any one of aspects 1-45, wherein the polymer or oligomer maintains a wet strain of up to about 300% for a period of up to four weeks. Aspect 47. The ocular implant of any one of aspects 1-46, wherein the polymer or oligomer is biodegradable. Aspect 48. The ocular implant of aspect 47, wherein the polymer or oligomer degrades over a time period from about one week to about six months. Aspect 49. A method of treating an ophthalmic disorder in a subject in need thereof comprising administering to the subject an ocular implant of any one of aspects 1-48. Aspect 50. The method of aspect 49, wherein the ocular implant is placed within or proximal to the eye. Aspect 51. The method of aspect 49 or 50, wherein the ocular implant is placed within an intracanalicular duct. Aspect 52. The method of aspect 49 or aspect 50, wherein the ocular implant is placed within a scleral membrane. Aspect 53. The method of aspect 49 or aspect 50, wherein the ocular implant is placed into a subconjunctival position and / or a parabular position. Aspect 54. The method of aspect 49 or aspect 50, wherein the ocular implant is placed into an intravitreal environment. Aspect 55. The method of any one of aspects 49-54, wherein the ophthalmic disorder comprises post-surgical inflammation, irritation, and / or infection. Aspect 56. The method of any one of aspects 49-54, wherein the ophthalmic disorder comprises macular degeneration, cystoid macular edema, dry eye, retinopathy, glaucoma, ocular hypertension, endophthalmitis, or allergic conjunctivitis. Aspect 57. The method of any one of aspects 49-56, wherein the subject is a human. Attorney Docket No.11196-112WO1 Aspect 58. The method of any one of aspects 49-57, wherein the ocular implant treats the ophthalmic disorder for a period from about one day to about six months. Aspect 59. A polymer or oligomer formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; ascorbic acid, or a salt or derivative thereof; and optionally one or more additional monomers. Aspect 60. A polymer or oligomer formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; one or more therapeutic agents; and optionally one or more additional monomers. Aspect 61. The polymer or oligomer of aspect 60, wherein the one or more therapeutic agents comprise at least two polymerizable functional groups. Aspect 62. The polymer or oligomer of aspect 60 or aspect 61, wherein the one or more therapeutic agents comprise an anti-inflammatory agent. Aspect 63. The polymer or oligomer of any one of aspects 60-62, wherein the one or more therapeutic agents comprises bromfenac. Aspect 64. The polymer or oligomer of any one of aspects 60-63, wherein the one or more therapeutic agents are covalently bound to the polymer or oligomer. Aspect 65. The polymer or oligomer of any one of aspects 60-64, wherein the one or more therapeutic agents are incorporated into a backbone of the polymer or oligomer or are a pendant group of the polymer or oligomer. A number of aspects of the disclosure have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and Attorney Docket No.11196-112WO1 scope of the disclosure. Accordingly, other aspects are within the scope of the following claims. By way of non-limiting illustration, examples of certain aspects of the present disclosure are given below. EXAMPLES The following examples are set forth below to illustrate the compositions, devices, and methods claimed herein, along with associated methods and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present disclosure, which are apparent to one skilled in the art. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric. There are numerous variations and combinations of reaction conditions, e.g., component concentrations, temperatures, pressures, and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the described process. Only reasonable and routine experimentation will be required to optimize such process conditions. POC-Xylitol (POC-X) POC-Xylitol (POC-X) is synthesized from the monomers citric acid, xylitol, and octanediol, each of which has demonstrated biocompatibility as well as anti-oxidant and anti-microbial potentials in the case of citric acid and anti-oxidant properties in the case of xylitol (see FIG.2). POC-X is synthesized via a one step, catalyst free polycondensation reaction of the combined monomers in the desired ratio via melting at 160°C for 10 minutes followed by polymerization at 140°C until reaction termination (see FIG. 3). The resulting prepolymer is then dissolved in an organic solvent followed by either lyophilization or purification via precipitation in deionized (DI) water and subsequent lyophilization. Dried prepolymer is then dissolved in an appropriate organic solvent for further use. POC-X Branched Prepolymer Network Attorney Docket No.11196-112WO1 The resulting prepolymer network comprises linear repeat units, branched crosslinking points (ester bonds) and pendent functional groups (hydroxyl and carboxyl groups) (see FIG. 4) allowing further network functionalization or thermal crosslinking to form solid polymers. POC-X Formulations POC-X is synthesized using monomer ratios of citrate:octanediol:xylitol between 0.11:0.11:0 to 0.11:0.03:0.08 (see FIG.5). Xylitol Content Increases Polymer Network Density POC-X displays decreasing molecular weights, increased densities, and decreased molecular weights between crosslinks (see FIGs. 6A-6C, respectively) with increased xylitol incorporation and thermal crosslinking. Tunable Network Density of POC-X Xylitol incorporation therefore results in an increasingly branched and dense prepolymer and polymer network (see FIG.7) Xylitol Content Influences Mechanics and Swelling; Differential Swelling of Films Increased polymer density and branching, combined with the large number of hydrogen bond interactions between xylitol hydroxyls leads to significant increases in mechanical strengths compared to POC without xylitol incorporation (up to >100MPa for POC-X vs <5MPa for POC), particularly when thermally crosslinked at higher temperatures / longer times (see FIG. 8A). Additionally, the increased hydrophilicity of xylitol can be utilized to increase swelling in hydrated states, dependent on xylitol content and thermal crosslinking condition (see FIG. 8B). Particularly, increasing crosslinking density can counteract increased hydrophilicity even at high xylitol contents and result in minimal or maximal volume increase if desired (see FIG.9). Xylitol Content Modulates Wet Mechanics – Rigid Plastic to Soft Elastic Transition Of particular interest, subjecting xylitol containing polymers to hydration results in significant shifts in mechanical properties from rigid plastics in the dry state to soft elastomers in the hydrated state (see FIGs. 10A-10C). Further, it can be seen that even at extended time periods up to 4 weeks, xylitol containing polymers maintain higher strengths than POC. This mechanical transition can be utilized to create strong materials / implants Attorney Docket No.11196-112WO1 capable of handling / insertion without damage while minimizing tissue irritation due to mechanical mismatch following implantation. Xylitol Content Influences Degradation Rate and Fluorescence Xylitol incorporation significantly decreases total degradation time compared to POC (36 weeks for POC vs. 12 and 6 weeks for X3 and X6, respectively) (see FIG. 11A). Degradation times can be further tuned from less than 2 weeks to greater than 6 months by altering xylitol content and crosslinking condition. Particularly, this contrasts with POC, which cannot be rapidly degraded. Additionally, the increased intra- and intermolecular interactions between carboxyl and hydroxyl groups in xylitol polymers results in significant fluorescence ranging from 250 to 650nm (blue to red) (see FIG. 11B). This intrinsic fluorescence can be utilized to track implant location as well as degradation. POC-X Displays Significant Bioactivity Toxicity of the leachable fraction of Xylitol containing polymers (small molecules released into cell culture media from polymer disks over 24 hours) was significantly decreased against both L929 and RAW 264.7 cells compared to POC (see FIGs. 12A-12B). Proliferation of L9292 cells on xylitol was significantly increased compared to POC (see FIG. 13). Xylitol containing polymer films display complete inhibition of both gram positive and gram-negative bacteria (see FIG. 14), indicating significant intrinsic anti- microbial potential. POC-Xylitol System: Strength of a Plastic, Compliance of an Elastomer Xylitol containing polymers thus represent a highly tunable system without material properties capable of modulation across orders of magnitude, opening avenues into diverse applications. High strength and high strength to weight ratios are further demonstrated (see FIG. 16). A single X3 polymer strip weighing approximately 150mg is capable of holding 10lbs of weight. Additionally, the rigid to elastic material transition is further demonstrated following incubation in simulated tear fluid for 24 hours. Simulated Tear Fluid Simulated tear fluid was utilized for further experiments (see FIG.17). X3 Polymers Display Multiwavelength Fluorescence Additional fluorescence results indicate that xylitol containing polymers (X3) have significant fluorescence (see FIGs. 18A-18B) and that polymer films display significant Attorney Docket No.11196-112WO1 blue, red, and green fluorescence (see FIG. 18C). Additionally, the ability to utilize laser cutting to create complex geometries from xylitol films indicates significant fabrication potential. Incorporation of Antioxidant Ascorbic Acid (X3AA) Further expanding the xylitol polymer family, addition of the strong antioxidant monomer ascorbic acid (see FIG.19A) results in a dark black polymer film capable of laser cutting into complex shapes (see FIG. 19B). Anti-oxidant properties are expected to synergize with anti-inflammatory potential to further increase treatment effectiveness. POC- X-AA was synthesized in an identical fashion to POC-X, incorporating ascorbic acid (AA) as an additional diol (see FIG.20). Ascorbic Acid Incorporation (X3AA) Enables Absorbance Properties POC-X-AA prepolymer and polymer maintains fluorescence properties (see FIG. 21A) while displaying significantly enhanced absorbance (See FIG. 21B). POC-X-AA has significant NIR absorbance compared to POC and X3 (see FIG. 22A), with a concentration dependent increase in absorbance (see FIG.22B). Ascorbic Acid Incorporation (X3AA) Enables Photoacoustic Properties Strong NIR absorbance of POC-X-AA led to exploration of its photoacoustic imaging properties in agar tissue phantoms at ~2.5 cm depth (see FIG. 23A) using a photoacoustic / ultrasound imaging system (see FIG. 23B). Both X3-AA prepolymer and films display significant photoacoustic signal from 700nm to 950nm (see FIGs. 24A-24C), indicating potential in photoacoustic and photothermal applications for imaging and therapy, respectively. X3-AA films display significant absorbance from 250nm to 1100nm (see FIGs. 25A-25B). X3 films display significant absorbance in the UV region from 250nm to 400nm as well. Thus, films could also be used to block harmful UV light while in the case of X3 allowing transparency in the visible region. X3 blocks UV light while allowing transmission of visible light (450nm-660nm) (see FIG. 26A). X3-AA has significant absorbance from 700nm to 1000nm (NIR region) (see FIG. 26B). These results further display the ability to block UV light as described above while also allowing visible light transmission or strong absorbance in the visible to NIR regions depending on requirement. Incorporation of Cysteine (X3-Cys) Enhances Fluorescence Attorney Docket No.11196-112WO1 Incorporation of cysteine, forming the fluorophore CA-Cys (see FIG. 27A) can further increase fluorescence of prepolymers (see FIGs. 27B-27C) and films (see FIG. 27D) for more effective imaging (X3-Cys). POC-X3-Cys was synthesized via the same procedure as POC-X and POC-X-AA, with the addition of L-Cysteine to form the fluorophore CA-Cys (see FIG.28). Incorporation of Bromfenac to POC-Xylitol The NSAID anti-inflammatory drug Na-Bromfenac was successfully incorporated into POC-X3 and POC-X3-AA either as an additional monomer during prepolymer synthesis or via physical mixing into pre-synthesized prepolymers to form POC-X3-B10 (10wt% Na-Bromfenac) or POC-X3-AA-B10 (see FIG. 29). Homogeneous films of POC- X3-B10 and POC-X3-AA-B10 mixed and POC-X3-B10 reacted were obtained following thermal crosslinking (see FIG. 30). FTIR analysis revealed Bromfenac incorporation in both prepolymers and films of POC-X3-B10 rxn (see FIG. 31A-31B, respectively). UV- VIS revealed Bromfenac incorporation in POC-X3-B10 rxn prepolymer while Bromfenac release was detected from POC-X3-B10 rxn films following incubation in simulated tear fluid for up to 7 days (see FIG.32). Degradation / Bromfenac Release in Simulated Tear Fluid Bromfenac containing films crosslinked for longer times remain stable for up to 5 weeks in simulated tear fluid while those crosslinked for shorter times degrade completely within 5 weeks, leaving behind a residue likely compose of Bromfenac (see FIG. 33). Prepolymers can be combined with NaCl salt followed by thermal crosslinking and salt leaching to form porous implants of sizes similar to commercial Dextenza intracanalicular implants, displaying significant fluorescence (see FIG.34). Injection Molded Urethane Strategy Highly reactive hexamethylene diisocyanate (HDI) can be used to create self-setting urethane doped polyester (sCUPEs) where the primary citrate polyester is crosslinked by a secondary urethane network at room temperature without catalyst (see FIG. 35). Liquid prepolymer solutions and HDI can be injection molded as pure polymers or composites containing salt or hydroxyapatite particles to create controlled implant morphologies (see FIG.36). Gelatin Microspheres for Delayed Drug Release Attorney Docket No.11196-112WO1 Microfluidic mixers can be used to create gelatin methacrylate microparticles loaded with drugs (Rhodamine B in the example) for incorporation within polymer implants to further modulate drug release (see FIGs. 37A-37B). Microparticles can be injected through a 23G surgical needle, indicating capability as injectable intravitreal or transscleral implants (see FIGs.38A-38B). POC-Xylitol-Itaconate (POC-X-I) Itaconic acid (anti-inflammatory and anti-microbial monomer) can be incorporated in POC-X to create POC-X-I for further intrinsic bioactivity (see FIG.39). Poly(Octamethylene Itaconate-Xylitol) (POI-X) Itaconic acid can be combined with xylitol and octanediol to form POI-X (see FIG. 40). Drug Release Materials implants can be synthesized / fabricated with various drugs or combinations of drugs including those treating age related macular degeneration (AMD) or diabetic retinopathy (axitinib), glaucoma and ocular hypertension (travoprost), steroids (dexamethasone or prednisolone), anti-dry eye agents (cyclosporin), or anti- inflammatory / anti-microbial agents (including itaconic acid and 4-hydroxybenzyl alcohol). Implants can be fabricated containing a desired drug directly mixed or reacted with the polymer matrix (see FIG. 41). Implants can incorporate drug containing nanoparticles or microspheres (see FIG. 42). Implants can contain multiple bioactive agents incorporated directly in the polymer matrix, physically mixed in the polymer matrix, or within nanoparticles / microspheres incorporated within the polymer (see FIG.43 and FIG.44). Tapered Implant Design Implants can be designed with tapering morphologies to better lodge in the intracanalicular duct (see FIG.45). Cytotoxicity – Full Degradation Products To prepare degradation products, 1 g polymer films were fully degraded in 10ml 2M NaOH solution, and 5N HCl was added to adjust the pH to be 7.2-7.4. Once centrifuged, the supernatant was filtered to be sterilized. Dilutions of degradation products were prepared using culture medium (L929: High glucose DMEM with 10% FBS and 1% antibiotics; B-3: Attorney Docket No.11196-112WO1 EMEM with 20% FBS and 1% antibiotics). Dilutions of degradation products were prepared using culture medium (1x, 3x, 5x and 10x). 10ul of each dilution was added to cells cultured in 96-well plates with 90ul cell culture medium. After culturing for 24 hours, CCK-8 evaluation was performed according to manufacturer’s instruction. Degradation solution (2M NaOH ph7.4) at 1x dilution was added as a control. L929: ATCC catalog number CCL-1, mouse fibroblasts B-3: ATCC catalog number CRL-3603, human eye epithelial cells Bromfenac 10 (POCX3AA Bromfenac 10) demonstrated a favorable cytotoxicity profile for both L929 and B-3 cells. While Bromfenac 20 (POCX3AA Bromfenac 20) is more toxic, at a 10x dilution, B-3 cell viability reaches above 80%, which is considered non-toxic. Cytotoxicity – Leachable Products To prepare leachable products, polymer films (thickness < 0.5 mm) were cut into round disks measuring approximately 1 cm² surface area at each side. These disks were placed individually in a 24-well plate and incubated with 670 µL of culture medium for 24 hours at 37°C. For L929 cells, the medium consisted of high glucose DMEM with 10% FBS and 1% antibiotics, while for B-3 cells, the medium was EMEM with 20% FBS and 1% antibiotics. Dilutions of the leachable products were then prepared using culture medium at concentrations of 1x, 3x, 5x, and 10x dilution. The leachable products from different polymers were collected and added to L929 or B-3 cells cultured in 96-well plates. After a 24-hour incubation, cell viability was assessed using a CCK-8 assay kit according to the manufacturer’s instructions.L929: ATCC catalog number CCL-1, mouse fibroblasts B-3: ATCC catalog number CRL-3603, human eye epithelial cells Both Bromfenac 10 (POCX3AA Bromfenac 10) and Bromfenac 20 (POCX3AA Bromfenac 20) exhibited a favorable cytotoxicity profile for L929 and B-3 cells compared to the control materials (POC, POCX3, and POCX3AA). At a 3x dilution, the relative viability of cells treated with all leachable products remained well above 80%. Cell Proliferation – Leachable Products To prepare leachable products, polymer films (thickness < 0.5 mm) were cut into round disks measuring approximately 1 cm² surface area at each side. These disks were placed individually in a 24-well plate and incubated with 670 µL of culture medium for 24 hours at 37°C. For L929 cells, the medium consisted of high glucose DMEM with 10% FBS Attorney Docket No.11196-112WO1 and 1% antibiotics, while for B-3 cells, the medium was EMEM with 20% FBS and 1% antibiotics. Dilutions of the leachable products were then prepared using culture medium at concentrations of 1x, 3x, 5x, and 10x dilution. The leachable products from different polymers were collected and added to L929 or B-3 cells cultured in 96-well plates. After 1, 2 and 3 days incubation, cell viability was assessed using a CCK-8 assay kit according to the manufacturer’s instructions. L929: ATCC catalog number CCL-1, mouse fibroblasts B-3: ATCC catalog number CRL-3603, human eye epithelial cells Both Bromfenac 10 (POCX3AA Bromfenac 10) and Bromfenac 20 ((POCX3AA Bromfenac 20) exhibited a favorable proliferation profile for L929 and B-3 cells compared to the control materials (POC, POCX3, and POCX3AA) and negative cell medium control. Incorporation of antioxidant ascorbic acid to CXBEs (X3AA) further tunes material properties The evidence of a biphasic degradation profile for xylitol (X3) and xylitol / ascorbic acid (X3AA) containing polymers following incubation in simulated tear fluid (FIG. 58A) is preferential in that within the initial 4-week treatment window, the polymers remain essentially stable, potentially ensuring continued residence within the tear duct, followed by rapid dissolution in the following weeks (4-8 and 4-12 for X3AA and X3, respectively). An additional, critical finding is the large and continuous swelling of X3AA within the 4-week (28 days) treatment window, which can be assumed to additionally enhance implant stability as well as drug release (FIG. 58B). Finally, in FIG. 58C, it is noted that pH remains stable throughout the full course of material degradation, indicating minimal adverse impact due to potential acidification during treatment. Together, these three results recommend xylitol- containing polymers in general and X3AA in particular as materials demonstrating necessary physical and environmental responsive properties for the desired application as a function of their chemistry. Incorporation of riboflavin enhances fluorescent imaging of X3AA Another aspect relates the further modification of the X3AA polymer base with fluorescent compounds, in particular, Riboflavin, toward improved dual imaging (fluorescence / photoacoustic). Riboflavin, a compound utilized clinically as both a fluorescent tracer to assess damage to the ocular structures and barriers (via infiltration of the dissolved fluorophore through the compromised ocular membrane into the interior eye Attorney Docket No.11196-112WO1 structures) as well as a blue light responsive free radical generator used to form crosslinks between collagen chains within the cornea, thus strengthening the tissue, is easily conjugated to the citrate-xylitol polymer similar to previously disclosed agents via esterification (FIG.59A). Resulting prepolymers (X3AA Rib) maintain the NIR absorbance of X3AA while doubling the fluorescence intensity (FIGs. 59B-59D). Additionally, the maximum excitation and emission wavelengths of the resulting prepolymer closely match those of commercially utilized Fluorescein dye, which along with its high contrast green / yellow fluorescence (as compared to the dark brown implant surface and the blue excitation lamp used in clinic) suggest its potential for implant visualization and tracking during and post-implantation (FIG.59E). Injection molding of sCUP-X3AA Riboflavin Additional results utilizing the previously disclosed self-setting polyurethane crosslinking method demonstrate its applicability to the above formulated X3AA Rib (sCUPE-X3AA Rib) as fabricated into various thin films, bulks, and implants maintaining fluorescence (FIG.60). Ex Vivo Insertion of sCUPE-X3AA Implants Finally, implantation testing on white New Zealand rabbit cadavers indicate that sCUPE-X3AA injection molded implants can be successfully inserted within the tear duct and visualized even in the absence of strong fluorescence due to their contrasting dark brown color compared to the surrounding tissues (FIG.61). Punctal Plug Design Additional implant designs include a punctal plug design (FIG. 62), incorporating the tapered design referenced in the previous claims along with a cap with a larger diameter than the body designed to adhere to the tissue surrounding the tear duct opening and prevent the implant from being dislodged and falling downward into the tear duct. The compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compositions and methods in addition to those shown and described herein are intended to Attorney Docket No.11196-112WO1 fall within the scope of the appended claims. Further, while only certain representative compositions and method steps disclosed herein are specifically described, other combinations of the compositions and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein; however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.

Claims

Attorney Docket No.11196-112WO1 WHAT IS CLAIMED IS:

1. An ocular implant comprising a polymer or oligomer formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; and optionally one or more additional monomers.

2. The ocular implant of claim 1, wherein the ocular implant is suitable for placement within or proximal to the eye.

3. The ocular implant of claim 1 or claim 2, wherein the ocular implant is suitable for placement within an intracanalicular duct.

4. The ocular implant of claim 1 or claim 2, wherein the ocular implant is suitable for placement within a scleral membrane.

5. The ocular implant of claim 1 or claim 2, wherein the ocular implant is suitable for placement into a subconjunctival position and / or a parabular position.

6. The ocular implant of claim 1 or claim 2, wherein the ocular implant is suitable for placement into an intravitreal environment.

7. The ocular implant of any one of claims 1-6, wherein the molar ratio of citric acid, or a salt or ester thereof, to 1,8-octanediol and xylitol is from about 3:1 to about 1:

3.

8. The ocular implant of any one of claims 1-7, wherein the molar ratio of 1,8- octanediol to xylitol is from about 3:1 to about 1:

3.

9. The ocular implant of any one of claims 1-8, wherein the one or more additional monomers comprise ascorbic acid, itaconic acid, tannic acid, gallic acid, 4-hydroxybenzyl alcohol, salts thereof, derivatives thereof, or combinations thereof.Attorney Docket No.11196-112WO1 10. The ocular implant of any one of claims 1-9, wherein the one or more additional monomers comprise ascorbic acid or a salt or derivative thereof.

11. The ocular implant of any one of claims 1-10, wherein the one or more additional monomers comprise itaconic acid or a salt or derivative thereof.

12. The ocular implant of any one of claims 1-11, wherein the one or more additional monomers comprise a primary amine.

13. The ocular implant of claim 12, wherein the primary amine comprises an amino acid or a salt or derivative thereof.

14. The ocular implant of claim 13, wherein the amino acid comprises serine or cysteine, or a salt or derivative thereof.

15. The ocular implant of any one of claims 1-14, wherein the one or more additional monomers comprise a fluorophore.

16. The ocular implant of claim 15, wherein the fluorophore comprises riboflavin.

17. The ocular implant of any one of claims 1-16, wherein the polymer or oligomer is crosslinked.

18. The ocular implant of claim 17, wherein the polymer or oligomer is thermally crosslinked.

19. The ocular implant of claim 17, wherein the polymer or oligomer is radically crosslinked.

20. The ocular implant of claim 17, wherein the polymer or oligomer is crosslinked by one or more crosslinkers.Attorney Docket No.11196-112WO1 21. The ocular implant of claim 20, wherein the one or more crosslinkers comprise one or more diisocyanates.

22. The ocular implant of any one of claims 1-21, further comprising one or more therapeutic agents.

23. The ocular implant of claim 22, wherein the one or more therapeutic agents comprise an anti-inflammatory agent, an antioxidant, or an antimicrobial agent.

24. The ocular implant of claim 22, wherein the one or more therapeutic agents are selected from sodium bromfenac, axitinib, travoprost, dexamethasone, prednisolone, cyclosporin, vancomycin, or combinations thereof.

25. The ocular implant of claim 22, wherein the one or more therapeutic agents comprises sodium bromfenac.

26. The ocular implant of any one of claims 22-25, wherein the one or more therapeutic agents are incorporated into the polymer or oligomer.

27. The ocular implant of claim 26, wherein the one or more therapeutic agents are covalently bound to the polymer or oligomer.

28. The ocular implant of claim 26, wherein the one or more therapeutic agents are incorporated into a backbone of the polymer or oligomer or are a pendant group of the polymer or oligomer.

29. The ocular implant of claim 26, wherein the one or more therapeutic agents are incorporated during synthesis of the polymer or oligomer.

30. The ocular implant of claim 26, wherein the one or more therapeutic agents are incorporated via physical mixing with the polymer or oligomer.Attorney Docket No.11196-112WO1 31. The ocular implant of claim 26, wherein the one or more therapeutic agents are encapsulated within particles.

32. The ocular implant of claim 31, wherein the particles are dispersed within the polymer or oligomer.

33. The ocular implant of claim 31 or claim 32, wherein the particles comprise nanoparticles or microspheres.

34. The ocular implant of any one of claims 31-33, wherein the particles comprise a citrate-containing polymer.

35. The ocular implant of any one of claims 31-34, wherein the particles comprise a polymer selected from poly(lactic acid), poly(caprolactone), poly(lactic-co-glycolic acid), gelatin, hyaluronic acid, collagen, or combinations thereof.

36. The ocular implant of any one of claims 31-35, wherein the one or more therapeutic agents are released from the ocular implants over a time period ranging from one day to six months.

37. The ocular implant of any one of claims 1-36, wherein the ocular implant has porosity.

38. The ocular implant of claim 37, wherein the porosity is formed via leaching of a porogen.

39. The ocular implant of claim 37, wherein the porosity is formed via gas foaming.

40. The ocular implant of claim 37, wherein the porosity is formed via thermally induced phase separation.

41. The ocular implant of any one of claims 1-40, wherein the polymer or oligomer has a tensile strength ranging from about 0.5 MPa to about 150 MPa in a dry state.Attorney Docket No.11196-112WO1 42. The ocular implant of any one of claims 1-41, wherein the polymer or oligomer has a tensile strain ranging from about 1% to about 200% in a dry state.

43. The ocular implant of any one of claims 1-42, wherein solution uptake by the polymer or oligomer results in volume swelling from about 1% to about 500%.

44. The ocular implant of any one of claims 1-43, wherein the polymer or oligomer maintains a wet mechanics of up to about 10 MPA for a period up to about four weeks.

45. The ocular implant of any one of claims 1-44, wherein the polymer or oligomer maintains a wet modulus of up to about 10 MPa for a period of up to about four weeks.

46. The ocular implant of any one of claims 1-45, wherein the polymer or oligomer maintains a wet strain of up to about 300% for a period of up to four weeks.

47. The ocular implant of any one of claims 1-46, wherein the polymer or oligomer is biodegradable.

48. The ocular implant of claim 47, wherein the polymer or oligomer degrades over a time period from about one week to about six months.

49. A method of treating an ophthalmic disorder in a subject in need thereof comprising administering to the subject an ocular implant of any one of claims 1-48.

50. The method of claim 49, wherein the ocular implant is placed within or proximal to the eye.

51. The method of claim 49 or 50, wherein the ocular implant is placed within an intracanalicular duct.

52. The method of claim 49 or claim 50, wherein the ocular implant is placed within a scleral membrane.Attorney Docket No.11196-112WO1 53. The method of claim 49 or claim 50, wherein the ocular implant is placed into a subconjunctival position and / or a parabular position.

54. The method of claim 49 or claim 50, wherein the ocular implant is placed into an intravitreal environment.

55. The method of any one of claims 49-54, wherein the ophthalmic disorder comprises post-surgical inflammation, irritation, and / or infection.

56. The method of any one of claims 49-54, wherein the ophthalmic disorder comprises macular degeneration, cystoid macular edema, dry eye, retinopathy, glaucoma, ocular hypertension, endophthalmitis, or allergic conjunctivitis.

57. The method of any one of claims 49-56, wherein the subject is a human.

58. The method of any one of claims 49-57, wherein the ocular implant treats the ophthalmic disorder for a period from about one day to about six months.

59. A polymer or oligomer formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; ascorbic acid, or a salt or derivative thereof; and optionally one or more additional monomers.

60. A polymer or oligomer formed from: citric acid, or a salt or derivative thereof; 1,8-octanediol; xylitol; one or more therapeutic agents; and optionally one or more additional monomers.Attorney Docket No.11196-112WO1 61. The polymer or oligomer of claim 60, wherein the one or more therapeutic agents comprise at least two polymerizable functional groups.

62. The polymer or oligomer of claim 60 or claim 61, wherein the one or more therapeutic agents comprise an anti-inflammatory agent.

63. The polymer or oligomer of any one of claims 60-62, wherein the one or more therapeutic agents comprises bromfenac.

64. The polymer or oligomer of any one of claims 60-63, wherein the one or more therapeutic agents are covalently bound to the polymer or oligomer.

65. The polymer or oligomer of any one of claims 60-64, wherein the one or more therapeutic agents are incorporated into a backbone of the polymer or oligomer or are a pendant group of the polymer or oligomer.

Images